300 results found.

Leukemia, Lymphoblastic, Acute Clinical Trial using Geriatric assessment adapted therapy; Stem cells autotransplantation

Gruppo Italiano Malattie EMatologiche dell'Adulto - Recruiting 60 years or older.
- 'Geriatric Assessment Adapted' Therapy for Ph- ALL Elderly Patients. GIMEMA Protocol LAL1104. EudraCT Code 2005-002156-17.
Geriatric assessment adapted therapy; Stem cells autotransplantation

B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Rec Clinical Trial using fludarabine phosphate; rituximab; total-body irradiation; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; cyclosporine; mycophenolate mofetil; laboratory biomarker analysis; pharmacological study

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial.
fludarabine phosphate; rituximab; total-body irradiation; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; cyclosporine; mycophenolate mofetil; laboratory biomarker analysis; pharmacological study

Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Clinical Trial using IPI-145; Ofatumumab

Infinity Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase 3 Study of IPI-145 Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (DUO).
IPI-145; Ofatumumab

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large Clinical Trial using GS-9973

Gilead Sciences - Recruiting 18 years or older.
- A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies.
GS-9973

Breast Neoplasms, Ovarian Neoplasms, Colonic Neoplasms, Prostatic Clinical Trial

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers.

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using bortezomib; mitoxantrone hydrochloride; etoposide; cytarabine; flow cytometry

Case Comprehensive Cancer Center - Recruiting 18 years to 70 years.
- A Phase I Study of Bortezomib in Combination With MEC (Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine) for Relapsed/ Refractory Acute Myelogenous Leukemia (AML).
bortezomib; mitoxantrone hydrochloride; etoposide; cytarabine; flow cytometry

Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck Clinical Trial using CC-115

Celgene Corporation - Recruiting 18 years or older.
- A Phase 1a/b, Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual DNA-PK and TOR Kinase Inhibitor, CC-115, Administered Orally to Subjects With Advanced Solid Tumors, and Hematologic Malignancies..
CC-115

Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Clinical Trial using IPI-145; Ofatumumab

Infinity Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Study of IPI-145 and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07.
IPI-145; Ofatumumab

Myelodysplastic Syndromes, or Leukemia, Myelomonocytic, Chronic Clinical Trial using Azacitidine; Volasertib

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label Phase I Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics and Efficacy of Intravenous Volasertib in Combination With Subcutaneous Azacitidine in Patients With Previously Untreated High-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Ineligible for High-intensity Therapy.
Azacitidine; Volasertib

Leukemia, Myeloid, Acute Clinical Trial using Volasertib

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label, Phase I Trial of Intravenous Once Every 2 Weeks Administration of BI 6727 (Volasertib) in Japanese Patients With Acute Myeloid Leukemia.
Volasertib

Leukemia, Myeloid, Acute Clinical Trial using placebo; volasertib; low dose cytarabine

Boehringer Ingelheim - Recruiting N/A or older.
- A Phase III Randomised, Double-blind, Controlled, Parallel Group Study of Intravenous Volasertib in Combination With Subcutaneous Low-dose Cytarabine vs. Placebo + Low-dose Cytarabine in Patients >=65 Years With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy.
placebo; volasertib; low dose cytarabine

Leukemia, or Neoplasms Clinical Trial using volasertib

Boehringer Ingelheim - Recruiting 2 years to 17 years.
- Open, Non-controlled, Dose Escalating Phase I Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Tolerability and Toxicity of Volasertib in Paediatric Patients From 2 Years to Less Than 18 Years of Age With Acute Leukaemia or Advanced Solid Tumour, for Whom no Effective Treatment is Known.
volasertib

Leukemia, Myeloid, Acute Clinical Trial using decitabine iv; volasertib iv infusion

Boehringer Ingelheim - Recruiting 60 years or older.
- An Open Label, Phase I/IIa, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Volasertib in Combination With Decitabine in Patients >= 65 Years With Acute Myeloid Leukemia.
decitabine iv; volasertib iv infusion

Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymph Clinical Trial using Blinatumomab

Amgen - Recruiting 18 years or older.
- A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE Antibody Blinatumomab in Adult Subjects With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia (Alcantara Study).
Blinatumomab

Leukemia, Lymphocytic, Chronic, B-Cell Clinical Trial using BI 836826

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase I, Open, Dose Escalation Trial With BI 836826 in Patients With Advanced Chronic Lymphocytic Leukaemia.
BI 836826

Leukemia, Myeloid, Acute Clinical Trial using BI 836858

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase I, Open Cohort Dose Escalation Trial With BI 836858 in Patients With Refractory or Relapsed Acute Myeloid Leukemia..
BI 836858

Leukemia, or Lymphoma Clinical Trial using Rasburicase; Allopurinol

M.D. Anderson Cancer Center - Recruiting N/A or older.
- A Randomized Phase 2 Study to Evaluate the Efficacy of Rasburicase in Patients at Risk for TLS During Two Cycles of Chemotherapy.
Rasburicase; Allopurinol

B-cell Childhood Acute Lymphoblastic Leukemia, Peripheral T-cell Clinical Trial using dexamethasone; mitoxantrone hydrochloride; temsirolimus; vincristine sulfate; pegaspargase; methotrexate; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 1 year to 21 years.
- A Phase 1 Study of Temsirolimus in Combination With Intensive Re-Induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma.
dexamethasone; mitoxantrone hydrochloride; temsirolimus; vincristine sulfate; pegaspargase; methotrexate; laboratory biomarker analysis; pharmacological study

T Cell Leukemia, Adult, Leukemia, Adult T-Cell, or T Cell Leukemi Clinical Trial using Ruxolitinib

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Phase II Trial Evaluating the Safety and Efficacy of Ruxolitinib in Patients With Smoldering and Chronic Adult T-cell Leukemia (ATL).
Ruxolitinib

Pulmonary Infiltrate New Clinical Trial using Microbiological analysis

Northside Hospital, Inc. - Recruiting 18 years to 80 years.
- A Prospective Assessment of the Diagnostic Utility of Emerging Laboratory Assessments Used in Conjunction With Fiberoptic Bronchoscopy (FOB) in Hematopoietic Stem Cell Transplant (HSCT) and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates.
Microbiological analysis

Disorder Related to Bone Marrow Transplantation, Leukemia, or Tra Clinical Trial using Fludarabine; Clofarabine; Busulfan; Thymoglobulin; Stem Cell Infusion; Tacrolimus; Methotrexate

M.D. Anderson Cancer Center - Recruiting 3 years to 70 years.
- A Randomized Study of Once Daily Fludarabine-Clofarabine Versus Fludarabine Alone Combined With Intervenous Busulfan Followed by Allogeneic Hemopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).
Fludarabine; Clofarabine; Busulfan; Thymoglobulin; Stem Cell Infusion; Tacrolimus; Methotrexate

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Burkitt Lym Clinical Trial using CPX-351

Children's Hospital Medical Center, Cincinnati - Recruiting 12 Months to 30 years.
- A Phase I/Pilot Study of CPX-351 for Children, Adolescents and Young Adults With Recurrent or Refractory Hematologic Malignancies.
CPX-351

Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, or Clinical Trial using cabozantinib-s-malate; sunitinib malate; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Randomized Phase II Study Comparing Cabozantinib With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma.
cabozantinib-s-malate; sunitinib malate; laboratory biomarker analysis

Lymphocytic Leukemia, Chronic, Lymphoma, B-Cell Clinical Trial using GDC-0853

Genentech - Recruiting 18 years or older.
- AN OPEN-LABEL, PHASE I, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0853 IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA.
GDC-0853

Leukemia, Myeloid, Acute Clinical Trial using 300 mg Oral Azacitidine; Placebo

Celgene Corporation - Recruiting 55 years or older.
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best-supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission.
300 mg Oral Azacitidine; Placebo

Lymphocytic Leukemia, Chronic Clinical Trial using GDC-0199 (ABT-199); Obinutuzumab

Genentech - Recruiting 18 years or older.
- A Phase Ib Multicenter Dose-Finding And Safety Study Of GDC-0199 And Obinutuzumab in Patients With Relapsed Or Refractory Or Previously Untreated Chronic Lymphocytic Leukemia.
GDC-0199 (ABT-199); Obinutuzumab

Lymphocytic Leukemia, Chronic Clinical Trial using GDC-0199 (ABT-199); rituximab [MabThera/Rituxan]; bendamustine

Genentech - Recruiting 18 years or older.
- A Phase Ib, Open-Label Study Evaluating the Safety and Pharmacokinetics of GDC-0199 (ABT-199) in Combination With Bendamustine/Rituximab (BR) in Patients With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia.
GDC-0199 (ABT-199); rituximab [MabThera/Rituxan]; bendamustine

Acute Leukemia Clinical Trial using FLT PET/CT; MRI

Masonic Cancer Center, University of Minnesota - Recruiting 18 years to 55 years.
- Positron Emission Tomography (PET) Imaging in Patients With High Risk Hematological Malignancies Receiving Total Body Irradiation (TBI) or Total Marrow Irradiation (TMI) as Part of a Hematopoietic Stem Cell Transplant.
FLT PET/CT; MRI

Leukemia, Myelogenous, Chronic Clinical Trial using Nilotinib

M.D. Anderson Cancer Center - Recruiting 16 years or older.
- Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Oral Nilotinib.
Nilotinib

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, or Myelodys Clinical Trial using Allopurinol; Keppra; Busulfan; Cyclophosphamide; Cyclosporine A; Mycophenolate mofetil; Allogeneic hematopoietic stem cell transplant; Filgrastim; antithymocyte globulin

Masonic Cancer Center, University of Minnesota - Recruiting N/A to 44 years.
- Busulfan and Cyclophosphamide Followed By Allogeneic Hematopoietic Cell Transplantation In Patients With Hematological Malignancies.
Allopurinol; Keppra; Busulfan; Cyclophosphamide; Cyclosporine A; Mycophenolate mofetil; Allogeneic hematopoietic stem cell transplant; Filgrastim; antithymocyte globulin

Leukemia, or Myelodysplastic Syndromes Clinical Trial using filgrastim; busulfan; cyclosporine; fludarabine phosphate; melphalan; mycophenolate mofetil; umbilical cord blood transplantation

Masonic Cancer Center, University of Minnesota - Recruiting N/A to 2 years.
- Hematopoietic Cell Transplantation in the Treatment of Infant Leukemia Using Double Umbilical Cord Transplantation.
filgrastim; busulfan; cyclosporine; fludarabine phosphate; melphalan; mycophenolate mofetil; umbilical cord blood transplantation

Leukemia Clinical Trial using sargramostim; busulfan; cyclophosphamide; dexamethasone; etoposide; bone marrow transplantation; hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; total-body irradiation

Masonic Cancer Center, University of Minnesota - Recruiting N/A to 70 years.
- Autologous Peripheral Blood Stem Cell Transplant for Acute Non-Lymphocytic Leukemia (ANLL).
sargramostim; busulfan; cyclophosphamide; dexamethasone; etoposide; bone marrow transplantation; hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; total-body irradiation

Acute Myelogenous Leukemia Clinical Trial using Fludarabine; Cytarabine; G-CSF (Filgrastim, Neupogen); Idarubicin

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia.
Fludarabine; Cytarabine; G-CSF (Filgrastim, Neupogen); Idarubicin

T-cell Lymphomas, T-cell Leukemia, Sezary Syndrome, Mycosis Fungo Clinical Trial using A-dmDT390-bisFv(UCHT1)

Angimmune LLC - Recruiting 18 years or older.
- A Phase I/II Study of A-dmDT390-bisFv(UCHT1) Fusion Protein in Patients With Surface CD3+ Malignant T Cell Diseases.
A-dmDT390-bisFv(UCHT1)

Leukemia, Lymphoma, or Multiple Myeloma and Plasma Cell Neoplasm Clinical Trial using busulfan; cyclophosphamide; Stem cell infusion; Total body irradiation

Masonic Cancer Center, University of Minnesota - Recruiting N/A to 55 years.
- Unrelated or Partially Matched Allogeneic Donor Stem Cells for Lymphoma, Myeloma, and Chronic Lymphocytic Leukemia.
busulfan; cyclophosphamide; Stem cell infusion; Total body irradiation

Juvenile Myelomonocytic Leukemia Clinical Trial using Stem Cell Transplant

Masonic Cancer Center, University of Minnesota - Recruiting N/A to 18 years.
- Hematopoietic Cell Transplantation in Children With Juvenile Myelomonocytic Leukemia.
Stem Cell Transplant

Chronic Myelogenous Leukemia Clinical Trial using nilotinib; imatinib

Novartis - Recruiting 16 years or older.
- A Randomized Phase Lll Study of Imatinib Dose Optimization Compared With Nilotinib in Patients With Chronic Myelogenous Leukemia and Suboptimal Response to Standard-dose Imatinib.
nilotinib; imatinib

Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Myeloid Leukemia, Mul Clinical Trial using Dasatinib; laboratory biomarker analysis

Barbara Ann Karmanos Cancer Institute - Recruiting 18 years or older.
- Phase I/II Study of Dasatinib in Recipients of Allogeneic Stem Cell Transplantation for Hematologic Malignancies..
Dasatinib; laboratory biomarker analysis

Osteonecrosis, Acute Lymphoblastic Leukaemia, or Lymphoblastic Ly Clinical Trial

Heinrich-Heine University, Duesseldorf - Recruiting 10 years to 18 years.
- Part I: Incidence, Clinical Course and Significance of MRI for Early Diagnosis of Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Part II: Susceptibility for Aseptic Osteonecroses in Children and Adolescents With Chemotherapy for ALL or LBL.

Acute Myeloid Leukemia Clinical Trial using IPH2102 at 0.1 mg/kg; IPH2102 at 1 mg/kg; Placebo (normal saline solution)

Innate Pharma - Recruiting 60 years to 80 years.
- Double-Blind Placebo-Controlled Randomized Phase 2 Study of IPH2102 as Maintenance Treatment in Elderly Patients With Acute Myeloid Leukemia (AML) in First Complete Remission.
IPH2102 at 0.1 mg/kg; IPH2102 at 1 mg/kg; Placebo (normal saline solution)

Solid Tumor, Ovarian Cancer, Non-small Cell Lung Cancer, Chronic Clinical Trial

Cancer Centre of Monoclonal Therapy, LLC - Recruiting 18 years or older.
- Prognostic Potential of Cell Surface Markers and Pim Kinases in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors.

Relapsed B-Cell Acute Lymphoblastic Leukemia Clinical Trial using leukapheresis or collection of PBMCs; cyclophosphamide; modified T cells

Memorial Sloan-Kettering Cancer Center - Recruiting N/A to 26 years.
- A Phase I Trial of Autologous T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia.
leukapheresis or collection of PBMCs; cyclophosphamide; modified T cells

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblast Clinical Trial using Sirolimus; Idarubicin; Cytarabine

Thomas Jefferson University - Recruiting 18 years or older.
- A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia.
Sirolimus; Idarubicin; Cytarabine

Chronic Myelogenous Leukemia Clinical Trial using Chart Review

M.D. Anderson Cancer Center - Recruiting N/A or older.
- Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial.
Chart Review

Leukemia Clinical Trial using Eltrombopag; Hypomethylating Agent (HMA)

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Phase II Study of Eltrombopag With or Without Continuation of Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS).
Eltrombopag; Hypomethylating Agent (HMA)

CML Clinical Trial using AMN107

Novartis - Recruiting 18 years or older.
- A Phase II Randomized, Multicenter Study of Treatment-free Remission in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients Who Achieve and Sustain MR4.5 After Switching to Nilotinib.
AMN107

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using clofarabine; total-body irradiation; cyclosporine; mycophenolate mofetil; peripheral blood stem cell transplantation; allogeneic hematopoietic stem cell transplantation; laboratory biomarker analysis; pharmacological study

Fred Hutchinson Cancer Research Center - Recruiting 2 years or older.
- A Phase II Study of Optimally Dosed Clofarabine in Combination With Low-Dose TBI to Decrease Relapse Rates After Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients With AML.
clofarabine; total-body irradiation; cyclosporine; mycophenolate mofetil; peripheral blood stem cell transplantation; allogeneic hematopoietic stem cell transplantation; laboratory biomarker analysis; pharmacological study

Leukemia Clinical Trial using Vosaroxin; Decitabine

M.D. Anderson Cancer Center - Recruiting 60 years or older.
- A Phase I/II Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome.
Vosaroxin; Decitabine

Leukemia Clinical Trial using Ruxolitinib

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Phase I Study of Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS).
Ruxolitinib

B Cell Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or W Clinical Trial using AVL-292

Celgene Corporation - Recruiting 18 years or older.
- Phase 1b, Escalating Dose Study of AVL-292, a Bruton's Tyrosine Kinase (Btk) Inhibitor, as Monotherapy in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia.
AVL-292

Leukemia Clinical Trial using Clofarabine; Idarubicin; Cytarabine; Fludarabine

M.D. Anderson Cancer Center - Recruiting 18 years to 60 years.
- Phase I/II Randomized Study of Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome.
Clofarabine; Idarubicin; Cytarabine; Fludarabine

Adult Acute Lymphoblastic Leukemia Clinical Trial using Vincristine Sulfate Liposome; Vincristine Sulfate

Nanjing Luye Sike Pharmaceutical Co.,Ltd. - Recruiting 18 years to 65 years.
- Phase III Study of Vincristine Sulfate Liposome Or Vincristine Sulfate For Injection Combined Chemotherapy as Initial Induction Regimen In Adults Acute Lymphoblastic Leukemia.
Vincristine Sulfate Liposome; Vincristine Sulfate

Leukemia Clinical Trial using Cladribine; Cytarabine; Decitabine

M.D. Anderson Cancer Center - Recruiting 60 years or older.
- Phase II Study of Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed By Consolidation With Cladribine Plus LDAC Alternating With Decitabine in Patients With Untreated Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).
Cladribine; Cytarabine; Decitabine

Leukemia, Lymphoma, Unspecified Adult Solid Tumor, Protocol Speci Clinical Trial using allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- An Evaluation of the Toxicity and Therapeutic Effects of Epstein-Barr Virus-Immune (EBV)-Immune T-Lymphocytes Derived From Normal HLA-Compatible or Haplotype-Matched Donor in the Treatment of EBV-Associated Lymphoproliferative Diseases or Malignancies and Patients With Detectable Circulating Levels of EBV DNA Who Are at High Risk for EBV-Associated Lymphoproliferative Diseases.
allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes

Leukemia Clinical Trial using Daunorubicin; Vincristine; Prednisone; PEG-Asparaginase; Methotrexate; 6-MP (6-Mercaptopurine); Cyclophosphamide; Cytarabine; Leucovorin; Dexamethasone

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years to 60 years.
- A Novel 'Pediatric-Inspired' Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia.
Daunorubicin; Vincristine; Prednisone; PEG-Asparaginase; Methotrexate; 6-MP (6-Mercaptopurine); Cyclophosphamide; Cytarabine; Leucovorin; Dexamethasone

Acute Myelogenous Leukemia, AML, or Acute Myeloid Leukemia Clinical Trial using ABT-199

AbbVie - Recruiting 18 years or older.
- A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML).
ABT-199

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adul Clinical Trial using cytarabine; lenalidomide

Roswell Park Cancer Institute - Recruiting 18 years or older.
- Phase I Trial of Cytarabine and Lenalidomide in Relapsed or Refractory Acute Myeloid Leukemia Patients.
cytarabine; lenalidomide

Acute Myeloid Leukemia (AML), or Myelodysplastic Syndrome (MDS) Clinical Trial using Treosulfan

Center for International Blood and Marrow Transplant Research - Recruiting N/A to 21 years.
- A Phase II Study of Treosulfan/Fludarabine/Low Dose Total Body Irradiation as a Preparative Regimen for Children With AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation.
Treosulfan

Acute Myeloid Leukemia (AML), or Myelodysplastic Syndrome (MDS) Clinical Trial

Fred Hutchinson Cancer Research Center - Recruiting 18 years to 80 years.
- Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Chemotherapy for Older and Medically Infirm Patients Diagnosed With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study.

Myelodysplastic Syndromes (MDS), or Acute Myelogenous Leukemia (A Clinical Trial using low dose 5'-azacitidine

Memorial Sloan-Kettering Cancer Center - Recruiting 1 year to 75 years.
- A Single Arm Phase II Trial of Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse.
low dose 5'-azacitidine

Acute Myeloid Leukemia Clinical Trial using DAC; CLAG; Consolidation, I HAM cycle; II Consolidation HiDAraC; Consolidation, III HiDAraC cycle

Polish Adult Leukemia Group - Recruiting 18 years to 60 years.
- Evaluation of the Efficacy of Induction-consolidation Treatment Using a Double Induction in Patients With AML <60 Years Old, Depending on the Percentage of Blasts in the 14 Day, Residual Disease and Leukemic Hematopoietic Cells.
DAC; CLAG; Consolidation, I HAM cycle; II Consolidation HiDAraC; Consolidation, III HiDAraC cycle

Neoplasms Clinical Trial using RO5503781

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multi-center, Open Label, First in Human Phase I Dose Escalation Study of Single Agent RO5503781, a Small Molecule MDM2 Antagonist, Administered Orally in Patients With Advanced Malignancies, Except Leukemia.
RO5503781

Myelogenous Leukemia, Acute Clinical Trial using RO5503781; cytarabine; Anthracycline

Hoffmann-La Roche - Recruiting 18 years or older.
- A MULTI-CENTER, OPEN-LABEL, PHASE 1/1B STUDY OF ESCALATING DOSES OF RO5503781 ADMINISTERED ORALLY AS 1) A SINGLE AGENT, 2) IN COMBINATION WITH CYTARABINE, OR 3) WITH CYTARABINE AND ANTHRACYCLINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML).
RO5503781; cytarabine; Anthracycline

Myelogenous Leukemia, Acute Clinical Trial using RO5429083; cytarabine

Hoffmann-La Roche - Recruiting 18 years or older.
- Open Label, Multicenter, Dose Escalation Phase 1a/b Study of RO5429083, Administered as Intravenous Infusion Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia (AML)..
RO5429083; cytarabine

Chronic Lymphocytic Leukemia Clinical Trial using obinutuzumab; chemotherapy

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multicenter, Open-label, Single-arm, Phase IIIb, International Study Evaluating the Safety of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia.
obinutuzumab; chemotherapy

Chronic Lymphocytic Leukemia Clinical Trial using GDC-0199; Rituximab [MabThera/Rituxan]; Bendamustine

Hoffmann-La Roche - Recruiting 18 years or older.
- A MULTICENTER, PHASE III, OPEN-LABEL, RANDOMIZED STUDY IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 (ABT-199) PLUS RITUXIMAB COMPARED WITH BENDAMUSTINE PLUS RITUXIMAB.
GDC-0199; Rituximab [MabThera/Rituxan]; Bendamustine

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using pravastatin sodium; idarubicin; cytarabine; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years to 74 years.
- Idarubicin, Cytarabine and Pravastatin (IAP) for Induction of Newly Diagnosed Acute Myeloid Leukemia (AML).
pravastatin sodium; idarubicin; cytarabine; laboratory biomarker analysis

Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Clinical Trial using Idelalisib; Rituximab; Bendamustine; Ofatumumab; Fludarabine; Everolimus; Bortezomib; Chlorambucil; Lenalidomide

Gilead Sciences - Recruiting 18 years or older.
- A Phase I Study to Investigate the Safety and Clinical Activity of Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 mAb in Subjects With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia.
Idelalisib; Rituximab; Bendamustine; Ofatumumab; Fludarabine; Everolimus; Bortezomib; Chlorambucil; Lenalidomide

Acute Myeloid Leukemia Clinical Trial using Phase1 and Phase 2: decitabine; Phase 1: cytarabine; Phase 2: cytarabine

Janssen Research & Development, LLC - Recruiting 1 Month to 18 years.
- Phase 1-2 Safety and Efficacy Study of DACOGEN in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia.
Phase1 and Phase 2: decitabine; Phase 1: cytarabine; Phase 2: cytarabine

Leukemia Clinical Trial using Dasatinib; Decitabine

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357).
Dasatinib; Decitabine

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myel Clinical Trial using fludarabine phosphate; cyclophosphamide; total-body irradiation; iodine I 131 monoclonal antibody BC8; allogeneic bone marrow transplantation; tacrolimus; mycophenolate mofetil

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Hematopoietic Bone Marrow Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Related HLA-Mismatched Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined With Immunosuppression Before and After Transplantation.
fludarabine phosphate; cyclophosphamide; total-body irradiation; iodine I 131 monoclonal antibody BC8; allogeneic bone marrow transplantation; tacrolimus; mycophenolate mofetil

Graft Versus Host Disease, Leukemia, or Lymphoma Clinical Trial using rituximab; fludarabine phosphate; melphalan; sirolimus; tacrolimus; allogeneic hematopoietic stem cell transplantation; indium In 111 ibritumomab tiuxetan; yttrium Y 90 ibritumomab tiuxetan; laboratory biomarker analysis

City of Hope Medical Center - Recruiting 18 years to 69 years.
- A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for B-Cell Non-Hodgkin Lymphoma Using Zevalin, Fludarabine and Melphalan.
rituximab; fludarabine phosphate; melphalan; sirolimus; tacrolimus; allogeneic hematopoietic stem cell transplantation; indium In 111 ibritumomab tiuxetan; yttrium Y 90 ibritumomab tiuxetan; laboratory biomarker analysis

Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic L Clinical Trial using Sotatercept

Celgene Corporation - Recruiting 18 years or older.
- An Open-label, Randomized, Phase 2, Parallel, Dose-ranging, Multicenter Study of Sotatercept for the Treatment of Patients With Anemia and Low- or Intermediate-1 Risk Myelodysplastic Syndromes or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)..
Sotatercept

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using standard follow-up care; medical chart review; quality-of-life assessment

Fred Hutchinson Cancer Research Center - Recruiting 18 years to 75 years.
- Phase 2 Study of Early Discharge and Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML.
standard follow-up care; medical chart review; quality-of-life assessment

Acute Myeloid Leukemia (AML), or Acute Lymphocytic Leukemia (ALL) Clinical Trial using CB-839

Calithera Biosciences, Inc - Recruiting 18 years or older.
- A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Relapsed and/or Treatment-Refractory Leukemia.
CB-839

Leukemia Clinical Trial using Busulfan; Clofarabine; Gemcitabine; Thymoglobulin; Allogeneic Stem Cell Transplantation; Filgrastim; Tacrolimus; Methotrexate

M.D. Anderson Cancer Center - Recruiting 18 years to 70 years.
- Clofarabine, Gemcitabine and Busulfan Followed by Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL).
Busulfan; Clofarabine; Gemcitabine; Thymoglobulin; Allogeneic Stem Cell Transplantation; Filgrastim; Tacrolimus; Methotrexate

Acute Lymphoblastic Leukemia Clinical Trial using VDCLD regimen

Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd. - Recruiting 14 years to 60 years.
- Pegylated Liposomal Doxorubicin-contained Versus Daunorubicin-contained VDCLD Regimen in Previously Untreated Adult Patients With Acute Lymphoblastic Leukemia: Complete Remission Rates and Changes of Leukemia Stem Cells.
VDCLD regimen

Chronic Lymphocytic Leukemia Clinical Trial using Idelalisib; Ofatumumab

Gilead Sciences - Recruiting 18 years or older.
- A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia.
Idelalisib; Ofatumumab

Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Clinical Trial using ACP-196

Acerta Pharma BV - Recruiting 18 years or older.
- A Phase 1, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects With Chronic Lymphocytic Leukemia.
ACP-196

Myeldysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia, B Clinical Trial using Clofarabine; Lenalidomide

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Clofarabine Followed by Lenalidomide for Treatment of High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Clofarabine; Lenalidomide

Leukemia, or Lymphoma Clinical Trial using HSCT; DLI

M.D. Anderson Cancer Center - Recruiting 1 year to 65 years.
- CD19-Specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation.
HSCT; DLI

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Clinical Trial using PCI-32765 (Ibrutinib)

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study.
PCI-32765 (Ibrutinib)

B-cell Childhood Acute Lymphoblastic Leukemia, Cognitive/Function Clinical Trial using cognitive assessment; psychosocial assessment and care; diffusion tensor imaging; laboratory biomarker analysis; pharmacological study

Children's Oncology Group - Recruiting 1 year to 17 years.
- A Study of Neurocognitive Function in Children Treated for ALL.
cognitive assessment; psychosocial assessment and care; diffusion tensor imaging; laboratory biomarker analysis; pharmacological study

Adult Acute Lymphoblastic Leukemia in Remission, Adult Nasal Type Clinical Trial using dasatinib; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517; IND-73969) in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction.
dasatinib; pharmacological study

Chronic Myeloid Leukemia Clinical Trial using nilotinib

Novartis - Recruiting N/A or older.
- A Phase II, Single Arm, Open Label Study of Treatment-free Remission in Chronic Myeloid Leukemia (CML) Chronic Phase (CP) Patients After Achieving Sustained MR4.5 on Nilotinib.
nilotinib

Leukemia, or Lymphoma Clinical Trial using Needs Analysis; Video game; Interview

M.D. Anderson Cancer Center - Recruiting 15 years to 29 years.
- Using Game Mechanics to Improve Outcomes Among Stem Cell Transplant Survivors.
Needs Analysis; Video game; Interview

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Clinical Trial using Anti-CD19-CAR Transduced PBL; Fludarabine; Cyclophosphamide; PG13-CD19-H3 (anti-CD19-CAR) transduced PBL)

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 68 years.
- Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With B-cell Lymphoma or Leukemia.
Anti-CD19-CAR Transduced PBL; Fludarabine; Cyclophosphamide; PG13-CD19-H3 (anti-CD19-CAR) transduced PBL)

Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphob Clinical Trial using Blinatumomab; Standard of Care Chemotherapy

Amgen - Recruiting 18 years or older.
- A Phase 3, Randomized, Open Label Study Investigating the Efficacy of the BiTE Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study).
Blinatumomab; Standard of Care Chemotherapy

Hematologic Neoplasms, Neural Tube Defects, or Myeloproliferative Clinical Trial using therapeutic allogeneic lymphocytes; Sirolimus

National Institutes of Health Clinical Center (CC) - Recruiting 11 years to 90 years.
- Allogeneic HSCT Without Preparative Chemotherapy or With Low-Intensity Preparative Chemotherapy Using Sirolimus and Sirolimus-Generated Donor Th2 Cells for Therapy of Refractory Leukemia, Lymphoma, Myeloma, or Myelodysplastic Syndrome.
therapeutic allogeneic lymphocytes; Sirolimus

Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disea Clinical Trial using Cyclophosphamide; rituximab; Methotrexate; Sirolimus; Cyclosporine; Doxorubicin hydrochloride; Etoposide; Fludarabine phosphate; Prednisone; Vincristine sulfate; Cytarabine; Tacrolimus; Alemtuzumab

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 74 years.
- Phase II Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Treatment of Leukemias, Lymphomas, and Pre-malignant Blood Disorders.
Cyclophosphamide; rituximab; Methotrexate; Sirolimus; Cyclosporine; Doxorubicin hydrochloride; Etoposide; Fludarabine phosphate; Prednisone; Vincristine sulfate; Cytarabine; Tacrolimus; Alemtuzumab

Adult T-Cell Leukemia (ATL) Clinical Trial using LMB-2; Fludarabine; Cyclophosphamide; LMB-2, anti-Tac(Fv)-PE38

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia.
LMB-2; Fludarabine; Cyclophosphamide; LMB-2, anti-Tac(Fv)-PE38

Monoclonal B-Cell Lymphocytosis Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers..

Hairy Cell Leukemia Clinical Trial using Ibrutinib

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 for Treatment of Relapsed Hairy Cell Leukemia.
Ibrutinib

Hairy Cell Leukemia Clinical Trial using Cladribine; Rituximab

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Randomized Trial of Cladribine (CdA) With Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual Disease.
Cladribine; Rituximab

Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), No Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Collection of Human Samples to Study Hairy Cell and Other Leukemias and to Develop Recombinant Immunotoxins for Cancer Treatment.

Leukemia, Lymphoma, Neuroblastoma, Sarcoma, or Desmoplastic Small Clinical Trial using Melphalan; Fludarabine; Cyclophosphamide; Cytarabine; Prednisone; Vincristine; Doxorubicin; Etoposide; Filgrastim; NK-DLI Infusions

National Institutes of Health Clinical Center (CC) - Recruiting 4 years to 35 years.
- A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias.
Melphalan; Fludarabine; Cyclophosphamide; Cytarabine; Prednisone; Vincristine; Doxorubicin; Etoposide; Filgrastim; NK-DLI Infusions

Lymphoproliferative Disorders Clinical Trial using Alemtuzumab (Campath)

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 85 years.
- Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Alemtuzumab (Campath).
Alemtuzumab (Campath)

Lymphoma, or Leukemia Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Blood and Lymph Node Malignancy.

Small Lymphocytic Lymphoma, or CLL (Chronic Lymphocytic Leukemia) Clinical Trial using Fludarabine Phosphate; Ofatumumab; Cyclophosphamide

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Study of Ofatumumab-Based Induction Chemoimmunotheraphy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Fludarabine Phosphate; Ofatumumab; Cyclophosphamide

Solid Tumor, Leukemia, or Neurofibromatosis Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 6 years or older.
- Validation of the English Version of the Pain Interference Index and the Pain Rating Scale in Children, Adolescents, and Young Adults With Chronic Illness and Their Parents.

Lung or Prostatic Neoplasms, Colorectal or Kidney Neoplasms, Panc Clinical Trial using NK cells +CliniMACs CD3 and CD56 systems

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 70 years.
- Safety and the Anti-Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK TRAIL Cytotoxicity With Bortezomib.
NK cells +CliniMACs CD3 and CD56 systems

Ewing's Sarcoma, Leukemia, Lymphoma, Neoplasm, or Sarcoma Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 3 Months to 40 years.
- Treatment of Children With Cancer.

Pediatric Cancer, Leukemia, Sarcoma, or Brain Tumors Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A to 18 years.
- Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN) Children s Oncology Group.

Childhood Acute Lymphoblastic Leukemia Clinical Trial using PEG-L-asparaginase ind; PEG-L-asparaginase cons; E.coli L-asparaginase; High-dose Methotrexate; Low-dose Methotrexate; Triple intrathecal therapy; Cranial irradiation; Daunorubicin

Federal Research Institute of Pediatric Hematology, Oncology and Immunology - Recruiting 1 year to 18 years.
- Moscow-Berlin 2008 Multicenter Randomised Study for Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents.
PEG-L-asparaginase ind; PEG-L-asparaginase cons; E.coli L-asparaginase; High-dose Methotrexate; Low-dose Methotrexate; Triple intrathecal therapy; Cranial irradiation; Daunorubicin

Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, or Leuk Clinical Trial using Allogeneic Lymphocytes; Fludarabine; Cyclophosphamide; Methylprednisolone; Cyclosporine

National Institutes of Health Clinical Center (CC) - Recruiting 8 years to 75 years.
- Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation.
Allogeneic Lymphocytes; Fludarabine; Cyclophosphamide; Methylprednisolone; Cyclosporine

Multiple Myeloma, Leukemia, MGUS, or MBL Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 50 years or older.
- Study of Biomarkers of Exposure and Effects in Agriculture.

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Lymphom Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol.

Non-Hodgkin Lymphoma, Multiple Myleoma, Chronic Lympocytic Leukem Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 79 years.
- A Multi-Center International Hospital-Based Case-Control Study of Lymphoma in Asia (AsiaLymph).

Aplastic Anemia, Leukemia, Myelodysplastic Syndrome (MDS), or Lym Clinical Trial using Cord Blood Units

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients.
Cord Blood Units

Acute Myeloid Leukemia Clinical Trial using pracinostat with azacitadine

MEI Pharma, Inc. - Recruiting 65 years or older.
- A Phase II Open-Label, Single-arm, Two-Stage, Multicenter Trial of Pracinostat in Combination With Azacitidine in Elderly (Age 65 Years or Older) Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
pracinostat with azacitadine

B-cell Chronic Lymphocytic Leukemia Clinical Trial using Lenalidomide; Placebo

Celgene Corporation - Recruiting 18 years or older.
- A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety of Lenalidomide (Revlimidr) as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia Following Second Line Therapy (THE CONTINUUM TRIAL).
Lenalidomide; Placebo

Leukemia Clinical Trial using Cytarabine; Lintuzumab-Ac225; Lasix; Spironolactone

M.D. Anderson Cancer Center - Recruiting 60 years or older.
- A Phase I/II Study of Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients With Untreated Acute Myeloid Leukemia.
Cytarabine; Lintuzumab-Ac225; Lasix; Spironolactone

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adul Clinical Trial using pretargeted radioimmunotherapy; cyclosporine; mycophenolate mofetil; total-body irradiation; nonmyeloablative allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; fludarabine phosphate; pharmacological study

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Hematopoietic Cell Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Radiolabeled DOTA-Biotin Pretargeted by BC8 Antibody-Streptavidin Conjugate.
pretargeted radioimmunotherapy; cyclosporine; mycophenolate mofetil; total-body irradiation; nonmyeloablative allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; fludarabine phosphate; pharmacological study

Leukemia, or Lymphoma Clinical Trial using DT2219ARL

Masonic Cancer Center, University of Minnesota - Recruiting 12 years or older.
- A Phase I Study of DT2219ARL, A Bispecific Singe Chain Immunotoxin for the Treatment of Relapsed or Refractory CD19(+), CD22(+) B-Lineage Leukemia or Lymphoma.
DT2219ARL

Chronic Lymphoid Leukemia Clinical Trial using Cholecalciferol; oleum neutralicum

Semmelweis University - Recruiting 18 years or older.
- Phase III, Controlled, Double-blind, Randomized Study of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases.
Cholecalciferol; oleum neutralicum

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using yttrium Y 90 anti-CD45 monoclonal antibody BC8; carmustine; etoposide; cytarabine; melphalan; peripheral blood stem cell transplantation; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- A Phase I/II Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Lymphoid Malignancies.
yttrium Y 90 anti-CD45 monoclonal antibody BC8; carmustine; etoposide; cytarabine; melphalan; peripheral blood stem cell transplantation; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocyt Clinical Trial using alemtuzumab; rituximab; PGG beta-glucan; flow cytometry; laboratory biomarker analysis; DNA analysis; fluorescence in situ hybridization; polymerase chain reaction; polymorphism analysis; mutation analysis

Mayo Clinic - Recruiting 18 years or older.
- Early Treatment of High Risk Chronic Lymphocytic Leukemia With Alemtuzumab, Rituximab, and PGG Beta-Glucan: A Phase I/II Trial.
alemtuzumab; rituximab; PGG beta-glucan; flow cytometry; laboratory biomarker analysis; DNA analysis; fluorescence in situ hybridization; polymerase chain reaction; polymorphism analysis; mutation analysis

Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphob Clinical Trial using Clofarabine; Mitoxantrone

New York Medical College - Recruiting N/A to 30 years.
- A Pilot Study of Mitoxantrone in Combination With Clofarabine (MITCL) in Children, Adolescents and Young Adults (CAYA) With Refractory/Relapsed Acute Leukemia or High Grade Non-Hodgkin Lymphoma.
Clofarabine; Mitoxantrone

Chronic Myeloid Leukemia Clinical Trial using Echo, exercise echo, and if indicated, right heart catheter

Medical University of Graz - Recruiting 18 years to 95 years.
- Pulmonary Vascular Changes in Patients With Chronic Myeloid Leukemia With Second-line Therapy Dasatinib vs. Nilotinib.
Echo, exercise echo, and if indicated, right heart catheter

Lymphocytic Leukemia, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Non Interventional Study Aimed to Describe the Management of Relapse or Refractory Chronic Lymphocytic Leukemia (CLL) Patients Retreated by MabThera.

Blood Stem Cell Transplant Failure, Leukemia, or Hematologic Mali Clinical Trial using Cyclophosphamide; Fludarabine; Melphalan; Mesna; Rituximab; Stem Cell Transplantation; Thiotepa; Tacrolimus; Mycofenolate mofetil; G-CSF

M.D. Anderson Cancer Center - Recruiting N/A to 75 years.
- Three-arm Clinical Trial for Patients With Hematologic Malignancies and Mismatched Donors - Haploidentical, 1 Antigen Mismatch Related or Unrelated, and Matched Unrelated Donor (MUD)- Using a T-cell Replete Allograft and High-dose Post-transplant Cyclophosphamide.
Cyclophosphamide; Fludarabine; Melphalan; Mesna; Rituximab; Stem Cell Transplantation; Thiotepa; Tacrolimus; Mycofenolate mofetil; G-CSF

Lymphoblastic Leukemia, Acute T-cell, or Precursor T-Cell Lymphob Clinical Trial using BMS-906024; Dexamethasone

Bristol-Myers Squibb - Recruiting 18 years or older.
- Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-906024 in Subjects With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma.
BMS-906024; Dexamethasone

B-cell Childhood Acute Lymphoblastic Leukemia, Philadelphia Chrom Clinical Trial using doxorubicin hydrochloride; cytarabine; vincristine sulfate; dexamethasone; pegaspargase; methotrexate; mercaptopurine tablet; leucovorin calcium; cyclophosphamide; thioguanine; quality-of-life assessment; questionnaire administration; laboratory biomarker analysis

Children's Oncology Group - Recruiting 1 year to 30 years.
- Treatment of Patients With Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL).
doxorubicin hydrochloride; cytarabine; vincristine sulfate; dexamethasone; pegaspargase; methotrexate; mercaptopurine tablet; leucovorin calcium; cyclophosphamide; thioguanine; quality-of-life assessment; questionnaire administration; laboratory biomarker analysis

Chronic Lymphocytic Leukemia Clinical Trial using Ofatumumab

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Ofatumumab Early Treatment for High-Risk Treatment-Naive, Early Stage (0-II) Patients With Chronic Lymphocytic Leukemia (CLL).
Ofatumumab

Chronic Lymphocytic Leukemia Clinical Trial using Ofatumumab

SCRI Development Innovations, LLC - Recruiting 18 years or older.
- Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia, a Phase II Trial.
Ofatumumab

Leukemia Clinical Trial using compliance monitoring; telephone-based intervention; mercaptopurine; computer-assisted intervention; counseling intervention; questionnaire administration; study of socioeconomic and demographic variables; standard follow-up care

Children's Oncology Group - Recruiting 6 Months to 25 years.
- A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL.
compliance monitoring; telephone-based intervention; mercaptopurine; computer-assisted intervention; counseling intervention; questionnaire administration; study of socioeconomic and demographic variables; standard follow-up care

Progressive Hairy Cell Leukemia, Initial Treatment, Refractory Ha Clinical Trial using ibrutinib; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia.
ibrutinib; laboratory biomarker analysis; pharmacological study

Cancer Clinical Trial using GSK1120212; Docetaxel + GSK1120212; Erlotinib + GSK1120212; Pemetrexed + GSK1120212; Carboplatin + GSK1120212; Nab-paclitaxel + GSK1120212; Gemcitabine + GSK1120212; Everolimus + GSK1120212

GlaxoSmithKline - Recruiting 18 years or older.
- MEK114375: A Rollover Study to Provide Continued Treatment With GSK1120212 to Subjects With Solid Tumors and Leukemia.
GSK1120212; Docetaxel + GSK1120212; Erlotinib + GSK1120212; Pemetrexed + GSK1120212; Carboplatin + GSK1120212; Nab-paclitaxel + GSK1120212; Gemcitabine + GSK1120212; Everolimus + GSK1120212

Leukemia Clinical Trial using Quizartinib; Cytarabine; AZA

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Phase I/II Study of the Combination of Quizartinib (AC220) With 5-Azacytidine or Low-Dose Cytarabine for the Treatment of Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Phase I/Phase II.
Quizartinib; Cytarabine; AZA

Acute Undifferentiated Leukemia, Atypical Chronic Myeloid Leukemi Clinical Trial using cytology specimen collection procedure

Children's Oncology Group - Recruiting N/A to 30 years.
- A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors.
cytology specimen collection procedure

Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Clinical Trial using laboratory biomarker analysis

Children's Oncology Group - Recruiting N/A to 21 years.
- Target: Identification for High Risk Childhood AML Based on Genome-Wide Analysis.
laboratory biomarker analysis

Leukemia, Myeloid, Acute Clinical Trial using Lenalidomide; Azacitidine

Washington University School of Medicine - Recruiting 18 years or older.
- Phase I/II Trial of Azacitidine Plus Lenalidomide in the Treatment of Acute Myeloid Leukemia.
Lenalidomide; Azacitidine

Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Clinical Trial using High Dose Methylprednisolone (HDMP); Ofatumumab; Lenalidomide

H. Lee Moffitt Cancer Center and Research Institute - Recruiting 18 years or older.
- Phase II Study of Ofatumumab in Combination With High Dose Methylprednisolone Followed by Ofatumumab and Lenalidomide Consolidative Therapy for the Treatment of Untreated CLL/SLL The HiLOG Trial.
High Dose Methylprednisolone (HDMP); Ofatumumab; Lenalidomide

Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Adu Clinical Trial using atorvastatin calcium; fludarabine phosphate; total-body irradiation; nonmyeloablative allogeneic hematopoietic stem cell transplantation; cyclosporine; mycophenolate mofetil; peripheral blood stem cell transplantation; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting N/A to 75 years.
- Donor Statin Treatment for Prevention of Severe Acute GVHD After Nonmyeloablative Hematopoietic Cell Transplantation.
atorvastatin calcium; fludarabine phosphate; total-body irradiation; nonmyeloablative allogeneic hematopoietic stem cell transplantation; cyclosporine; mycophenolate mofetil; peripheral blood stem cell transplantation; laboratory biomarker analysis

Acute Myeloid Leukemia, or Acute Lymphoblastic Leukemia Clinical Trial using WT1 peptide vaccine

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Phase II Trial of a WT-1 Analog Peptide Vaccine in Patients in Complete Remission (CR) From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL).
WT1 peptide vaccine

Blood Cancer, or Leukemia Clinical Trial using cyclosporine; Thymoglobulin; mycophenolate mofetil; g-csf

Stanford University - Recruiting N/A to 70 years.
- Allogeneic Hematopoietic Cell Transplantation Using a Non-Myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Older Patients With Hematologic Malignancies.
cyclosporine; Thymoglobulin; mycophenolate mofetil; g-csf

Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Ac Clinical Trial using supersaturated calcium phosphate rinse; placebo; questionnaire administration; quality-of-life assessment

Children's Oncology Group - Recruiting 4 years to 21 years.
- A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation.
supersaturated calcium phosphate rinse; placebo; questionnaire administration; quality-of-life assessment

Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leu Clinical Trial using ex vivo-expanded cord blood progenitor cell infusion; umbilical cord blood transplantation; double-unit umbilical cord blood transplantation; fludarabine phosphate; cyclophosphamide; total-body irradiation; cyclosporine; mycophenolate mofetil; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 6 Months to 45 years.
- Multi-center, Open-label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation With or Without Infusion of Off-The-shelf ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients With Hematologic Malignancies.
ex vivo-expanded cord blood progenitor cell infusion; umbilical cord blood transplantation; double-unit umbilical cord blood transplantation; fludarabine phosphate; cyclophosphamide; total-body irradiation; cyclosporine; mycophenolate mofetil; laboratory biomarker analysis

Leukemia, Lymphoma, or Hematologic Diseases Clinical Trial using collection and storage of tissue samples for research

Stanford University - Recruiting N/A to 70 years.
- Bone Marrow Grafting for Leukemia and Lymphoma.
collection and storage of tissue samples for research

Untreated Adult Acute Lymphoblastic Leukemia, or Untreated Childh Clinical Trial using laboratory biomarker analysis

Children's Oncology Group - Recruiting N/A to 30 years.
- Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL).
laboratory biomarker analysis

Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia, Chronic Clinical Trial using clofarabine; cytarabine; busulfan; Plerixafor; cyclophosphamide; antithymocyte globulin (rabbit); stem cells; Tacrolimus; mycophenolate mofetil

St. Jude Children's Research Hospital - Recruiting N/A to 21 years.
- T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant.
clofarabine; cytarabine; busulfan; Plerixafor; cyclophosphamide; antithymocyte globulin (rabbit); stem cells; Tacrolimus; mycophenolate mofetil

Juvenile Myelomonocytic Leukemia Clinical Trial using busulfan; cyclophosphamide; melphalan; fludarabine phosphate; allogeneic hematopoietic stem cell transplantation; pharmacological study; laboratory biomarker analysis

Children's Oncology Group - Recruiting 3 Months to 18 years.
- A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Children With Juvenile Myelomonocytic Leukemia (JMML).
busulfan; cyclophosphamide; melphalan; fludarabine phosphate; allogeneic hematopoietic stem cell transplantation; pharmacological study; laboratory biomarker analysis

Acute Myeloid Leukemia Clinical Trial using PF-04449913; Low dose ARA-C (LDAC); Decitabine; Daunorubicin; Cytarabine; Pf-04449913

Pfizer - Recruiting 18 years or older.
- A Phase 1B/2 Study To Evaluate The Safety And Efficacy Of PF-04449913, An Oral Hedgehog Inhibitor, In Combination With Intensive Chemotherapy, Low Dose Ara-C Or Decitabine In Patients With Acute Myeloid Leukemia Or High Risk Myelodysplastic Syndrome.
PF-04449913; Low dose ARA-C (LDAC); Decitabine; Daunorubicin; Cytarabine; Pf-04449913

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, CLL, or Clinical Trial using A6

ngstrom Pharmaceuticals - Recruiting 18 years or older.
- A Phase 2 Trial to Determine the Safety, Tolerability, and Efficacy of A6, a CD44 Binding Peptide, for the Treatment of Patients With Chronic Lymphocytic Leukemia.
A6

Leukemia Clinical Trial using anti-thymocyte globulin; busulfan; cyclophosphamide; cyclosporine; methotrexate; methylprednisolone; tacrolimus; laboratory biomarker analysis; pharmacological study; allogeneic bone marrow transplantation; allogeneic hematopoietic stem cell transplantation

Children's Oncology Group - Recruiting N/A to 30 years.
- Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Cell Transplantation (SCT) for AML With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children's Oncology Group (COG) Study.
anti-thymocyte globulin; busulfan; cyclophosphamide; cyclosporine; methotrexate; methylprednisolone; tacrolimus; laboratory biomarker analysis; pharmacological study; allogeneic bone marrow transplantation; allogeneic hematopoietic stem cell transplantation

Neurocognitive Impairment, or Acute Lymphoblastic Leukemia Clinical Trial using Neurocognitive and behavioral evaluation

St. Jude Children's Research Hospital - Recruiting 8 years or older.
- Risk of Psychopathology and Neurocognitive Impairment in Leukemia Survivors.
Neurocognitive and behavioral evaluation

Leukemia, Lymphoid Malignancies, or Metastatic Malignant Neoplasm Clinical Trial using Intrathecal Rituximab

M.D. Anderson Cancer Center - Recruiting 3 years or older.
- Safety and Efficacy of Intrathecal Rituximab in Patients With Lymphoid Malignancies Involving the Central Nervous System.
Intrathecal Rituximab

Leukemia Clinical Trial using Eltrombopag

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Eltrombopag for the Management of Thrombocytopenia Associated With Tyrosine Kinase Therapy in Patients With Chronic Myeloid Leukemia (CML).
Eltrombopag

Acute Myelogenous Leukemia Clinical Trial using MLN4924 and azacitidine

Millennium Pharmaceuticals, Inc. - Recruiting 60 years or older.
- A Phase 1b, Open-Label, Dose-Escalation Study of MLN4924 Plus Azacitidine in Treatment-Na‹ve Patients With Acute Myelogenous Leukemia Who Are 60 Years or Older.
MLN4924 and azacitidine

Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML); Clinical Trial using CliniMACS CD34+ Reagent System; Thiotepa; Cyclophosphamide; Alemtuzumab; Tacrolimus; Melphalan; Busulfan; Fludarabine

Columbia University - Recruiting N/A to 22 years.
- CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplant for Malignant Disease.
CliniMACS CD34+ Reagent System; Thiotepa; Cyclophosphamide; Alemtuzumab; Tacrolimus; Melphalan; Busulfan; Fludarabine

Chronic Kidney Disease, Acute Myeloid Leukemia (AML), Acute Lymph Clinical Trial using Haploidentical Bone Marrow/Kidney

Massachusetts General Hospital - Recruiting 18 years to 70 years.
- Combined Haploidentical Reduced Intensity Bone Marrow and Kidney Transplantation for Patients With Chronic Kidney Disease and Advanced Hematological Disorders.
Haploidentical Bone Marrow/Kidney

Lymphocytic Leukemia, Chronic Clinical Trial using rituximab [MabThera]; fludarabine; cyclophosphamide; chlorambucil

Hoffmann-La Roche - Recruiting 60 years or older.
- Prospective Randomized Study to Compare Efficacy and Safety of RFC-lite (Rituximab, Fludarabine, Cyclophosphamide) Regimen With LR (Rituximab, Chlorambucil) as a First-line Therapy in Patients With B-cell Chronic Lymphocytic Leukemia and Unfavorable Somatic Status.
rituximab [MabThera]; fludarabine; cyclophosphamide; chlorambucil

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using cytarabine; daunorubicin hydrochloride; idarubicin; vorinostat; allogeneic hematopoietic stem cell transplantation; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years to 60 years.
- A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin With High Dose Cytarabine (IA) Versus IA With Vorinostat (NSC-701852) (IA+V) in Younger Patients With Previously Untreated Acute Myeloid Leukemia (AML).
cytarabine; daunorubicin hydrochloride; idarubicin; vorinostat; allogeneic hematopoietic stem cell transplantation; laboratory biomarker analysis

Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myel Clinical Trial using Hedgehog inhibitor PF-04449913

University of Colorado, Denver - Recruiting 18 years or older.
- A Phase 2 Study of PF-04449913 for the Treatment of Acute Leukemia Patients With High Risk of Post-Allogeneic Stem Cell Transplantation Relapse.
Hedgehog inhibitor PF-04449913

Leukemia Clinical Trial using Moxetumomab Pasudotox

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Phase I/II Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL).
Moxetumomab Pasudotox

B-cell Acute Lymphoblastic Leukemia Clinical Trial using anti-CD19 redirected NK cells

National University Health System, Singapore - Recruiting 6 Months to 80 years.
- Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia.
anti-CD19 redirected NK cells

Acute Myeloid Leukemia Clinical Trial using Sapacitabine and decitabine; Decitabine

Cyclacel Pharmaceuticals, Inc. - Recruiting 70 years or older.
- A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia.
Sapacitabine and decitabine; Decitabine

Acute Lymphocytic Leukemia Clinical Trial using Inotuzumab Ozogamicin

Pfizer - Recruiting 18 years or older.
- An Open-Label, Phase 1/2 Study Of Inotuzumab Ozogamicin In Subjects With Relapsed Or Refractory CD22-Positive Acute Lymphocytic Leukemia.
Inotuzumab Ozogamicin

Leukemia, Myeloid, Ph1-Positive Clinical Trial using Nilotinib

Novartis - Recruiting 18 years or older.
- A Prospective, Randomized, Open Label, Two Arm Phase III Study to Evaluate Treatment Free Remission (TFR) Rate in Patients With Philadelphia-positive CML After Two Different Durations of Consolidation Treatment With Nilotinib 300mg BID.
Nilotinib

Leukemia, or Chronic Lymphocytic Leukemia Clinical Trial using Lenalidomide; Fludarabine monophosphate; Melphalan; NK Infusion; CB Infusion; Tacrolimus; Mycophenolate mofetil; Rituximab

M.D. Anderson Cancer Center - Recruiting 18 years to 75 years.
- Natural Killer Cells In Allogeneic Cord Blood Transplantation.
Lenalidomide; Fludarabine monophosphate; Melphalan; NK Infusion; CB Infusion; Tacrolimus; Mycophenolate mofetil; Rituximab

High Risk Acute Myeloid Leukemia Clinical Trial using CPX-351; 7+3 (cytarabine and daunorubicin)

Celator Pharmaceuticals - Recruiting 60 years to 75 years.
- Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age With Untreated High Risk (Secondary) AML.
CPX-351; 7+3 (cytarabine and daunorubicin)

B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Rec Clinical Trial using ofatumumab; dinaciclib; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase 1b/2 Study of Dinaciclib (SCH 727965) and Ofatumumab in Relapsed and Refractory CLL/SLL/B-PLL.
ofatumumab; dinaciclib; laboratory biomarker analysis; pharmacological study

B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Clinical Trial using ipilimumab; rituximab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of Ipilimumab in Combination With Rituximab in Patients With Relapsed/Refractory CD20+ B-Cell Lymphoma.
ipilimumab; rituximab; laboratory biomarker analysis

Blood And Marrow Transplantation, Leukemia, Lymphoma, Transplanta Clinical Trial using Melphalan; Fludarabine; Mycophenolate mofetil; Tacrolimus; Cord Blood Infusion; Rituximab; ATG; Busulfan; Clofarabine; Total Body Irradiation (TBI)

M.D. Anderson Cancer Center - Recruiting 1 year to 80 years.
- Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies.
Melphalan; Fludarabine; Mycophenolate mofetil; Tacrolimus; Cord Blood Infusion; Rituximab; ATG; Busulfan; Clofarabine; Total Body Irradiation (TBI)

Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Le Clinical Trial using sorafenib tosylate; bone marrow transplantation; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Pilot Study of Sorafenib in Patients With Acute Myeloid Leukemia as Peri-Transplant Remission Maintenance.
sorafenib tosylate; bone marrow transplantation; laboratory biomarker analysis

Advanced Cancers, or Leukemia Clinical Trial using Leukapheresis; Fludarabine; Cyclophosphamide; T-cell Infusion

M.D. Anderson Cancer Center - Recruiting 18 years to 80 years.
- Autologous CD19 Specific T-cell Infusion in Patients With B-cell Chronic Lymphocytic Leukemia (B-CLL).
Leukapheresis; Fludarabine; Cyclophosphamide; T-cell Infusion

Leukemia Clinical Trial using Cyclophosphamide; Mesna; Doxorubicin; Vincristine; Dexamethasone; Ofatumumab; Methotrexate; Cytarabine

M.D. Anderson Cancer Center - Recruiting N/A or older.
- Phase II Study of the Hyper - CVAD Regimen in Combination With Ofatumumab as Frontline Therapy for Patients With CD-20 Positive Acute Lymphoblastic Leukemia.
Cyclophosphamide; Mesna; Doxorubicin; Vincristine; Dexamethasone; Ofatumumab; Methotrexate; Cytarabine

Adult Acute Lymphoblastic Leukemia in Remission, Adult Grade III Clinical Trial using plerixafor; filgrastim; etoposide; leukapheresis

Case Comprehensive Cancer Center - Recruiting 18 years to 78 years.
- A Study of Hematopoietic Stem Cell Supermobilization in Patients With Non-Hodgkin Lymphoma.
plerixafor; filgrastim; etoposide; leukapheresis

Acute Myeloid Leukemia Clinical Trial using PGX-ODSH-2013-AML-1

Cantex Pharmaceticals - Recruiting 18 years to 80 years.
- A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2 O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia.
PGX-ODSH-2013-AML-1

Mature B-Cell Lymphoma Clinical Trial using COPAD; COP, COPD M3, CYM; COP, COPADM8, CYVE

St. Jude Children's Research Hospital - Recruiting N/A to 21 years.
- Mature B-Cell Lymphoma And Leukemia Study III.
COPAD; COP, COPD M3, CYM; COP, COPADM8, CYVE

Chronic Myelomonocytic Leukemia Clinical Trial

University of Arkansas - Recruiting 18 years or older.
- The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia.

Chronic Myeloid Leukemia Clinical Trial using Nilotinib

Novartis - Recruiting 18 years or older.
- Extending Molecular Responses With Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients in Chronic Phase.
Nilotinib

Chronic Phase Chronic Myeloid Leukemia Clinical Trial using Dasatinib

Bristol-Myers Squibb - Recruiting 18 years or older.
- Open-Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) With Stable Complete Molecular Response (CMR) DASFREE.
Dasatinib

Acute Leukemias of Ambiguous Lineage, Bacterial Infection, Diarrh Clinical Trial using levofloxacin

Children's Oncology Group - Recruiting 6 Months to 21 years.
- A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT).
levofloxacin

B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Diffuse Clinical Trial using rituximab; prednisone; etoposide; doxorubicin hydrochloride; cytarabine; vincristine sulfate; cyclophosphamide; methotrexate; methylprednisolone; leucovorin calcium; therapeutic hydrocortisone

Children's Oncology Group - Recruiting N/A to 18 years.
- Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients.
rituximab; prednisone; etoposide; doxorubicin hydrochloride; cytarabine; vincristine sulfate; cyclophosphamide; methotrexate; methylprednisolone; leucovorin calcium; therapeutic hydrocortisone

Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leu Clinical Trial using survey administration; assessment of therapy complications; long-term screening; study of high risk factors

Children's Oncology Group - Recruiting N/A or older.
- Umbrella Long-Term Follow-Up Protocol.
survey administration; assessment of therapy complications; long-term screening; study of high risk factors

Leukemia, or Acute Lymphoblastic Leukemia Clinical Trial using gene-modified T cells targeted to B-ALL tumor cells

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase I Trial of Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19.
gene-modified T cells targeted to B-ALL tumor cells

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adul Clinical Trial using iodine I 131 monoclonal antibody BC8; fludarabine phosphate; total-body irradiation; allogeneic hematopoietic stem cell transplantation; cyclosporine; mycophenolate mofetil; peripheral blood stem cell transplantation

Fred Hutchinson Cancer Research Center - Recruiting 16 years to 50 years.
- A Phase II Trial Combining Radiolabeled BC8 (Anti-CD45) Antibody With Fludarabine and Low Dose TBI Followed by Related or Unrelated PBSC Infusion and Post-Transplant Immunosuppression for Patients With Advanced AML or High Risk Myelodysplastic Syndrome.
iodine I 131 monoclonal antibody BC8; fludarabine phosphate; total-body irradiation; allogeneic hematopoietic stem cell transplantation; cyclosporine; mycophenolate mofetil; peripheral blood stem cell transplantation

Acute Myeloid Leukemia Clinical Trial using AZD1208

AstraZeneca - Recruiting 18 years or older.
- A Phase Ia/Ib, Open-Label, Multicentre, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 Administered Daily in Adult Patients With Recurrent or Refractory Acute Myelogenous Leukemia (AML).
AZD1208

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using caspofungin acetate; fluconazole; laboratory biomarker analysis

Children's Oncology Group - Recruiting 3 Months to 30 years.
- A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML).
caspofungin acetate; fluconazole; laboratory biomarker analysis

Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemi Clinical Trial using decitabine; mitoxantrone hydrochloride; etoposide; cytarabine; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming With Decitabine in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS): A Phase 1/2 Study.
decitabine; mitoxantrone hydrochloride; etoposide; cytarabine; laboratory biomarker analysis

Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymph Clinical Trial using Fludarabine phosphate; Thiotepa; Total body irradiation; Therapeutic allogeneic lymphocytes; Cyclophosphamide; Allogeneic hematopoietic stem cell transplantation (HSCT); Peripheral blood stem cell transplantation; Tacrolimus; Mycophenolate mofetil

Thomas Jefferson University - Recruiting 18 years or older.
- A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies.
Fludarabine phosphate; Thiotepa; Total body irradiation; Therapeutic allogeneic lymphocytes; Cyclophosphamide; Allogeneic hematopoietic stem cell transplantation (HSCT); Peripheral blood stem cell transplantation; Tacrolimus; Mycophenolate mofetil

Hematologic Malignancies Clinical Trial using in vitro expanded Cytokine Induced Killer (CIK) cells

A.O. Ospedale Papa Giovanni XXIII - Recruiting 18 years to 65 years.
- Sequential Infusion of Unmanipulated Donor Lymphocytes and Cytokine Induced Killer (CIK)Cells After Allogeneic Stem Cell Transplantation.
in vitro expanded Cytokine Induced Killer (CIK) cells

Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chr Clinical Trial using Fludarabine monophosphate; Busulfan; Stem Cell Infusion; Tacrolimus; Methotrexate; G-CSF

M.D. Anderson Cancer Center - Recruiting 5 years to 75 years.
- Randomized Phase II Study of Timed Sequential Busulfan in Combination With Fludarabine in Allogeneic Stem Cell Transplantation.
Fludarabine monophosphate; Busulfan; Stem Cell Infusion; Tacrolimus; Methotrexate; G-CSF

Acute Myeloid Leukemia Clinical Trial using Multiplex respiratory viral PCR

Centre Hospitalier Universitaire, Amiens - Recruiting 18 years to 85 years.
- Incidence of Respiratory Viral Infections During AML Induction and Consolidation Chemotherapy.
Multiplex respiratory viral PCR

Hematologic Malignancy, Leukemia, Acute Lymphoblastic Leukemia, A Clinical Trial using Total Body Irradiation (TBI); Donor Lymphocyte Infusion (DLI); Cyclophosphamide (CY); Tacrolimus; Mycophenolate Mofetil (MMF); Hematopoietic Stem Cell Transplant (HSCT)

Thomas Jefferson University - Recruiting 18 years or older.
- A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using Two Related Donors.
Total Body Irradiation (TBI); Donor Lymphocyte Infusion (DLI); Cyclophosphamide (CY); Tacrolimus; Mycophenolate Mofetil (MMF); Hematopoietic Stem Cell Transplant (HSCT)

Acute Lymphoblastic Leukemia Clinical Trial using Everolimus; Prednisone; Vincristine; PEG-Asparaginase; Doxorubicin; Dexrazoxane

Dana-Farber Cancer Institute - Recruiting 18 Months to 21 years.
- A Feasibility Trial of Everolimus (RAD001),an mTOR Inhibitor, Given in Combination With Multiagent Re-Induction Chemotherapy in Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia (ALL).
Everolimus; Prednisone; Vincristine; PEG-Asparaginase; Doxorubicin; Dexrazoxane

Relapsed Lymphoblastic Leukemia, Relapsed Lymphoblastic Lymphoma, Clinical Trial using Sirolimus

Children's Hospital Medical Center, Cincinnati - Recruiting N/A to 30 years.
- Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma.
Sirolimus

Bone Marrow Transplant Infection, Infection in Marrow Transplant Clinical Trial using Ribavirin

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- An Open Label Randomized Controlled Trial To Prevent the Progression of Respiratory Syncytial Virus Upper Respiratory Tract Infection to Lower Respiratory Tract Infection in Patients After Hematopoietic Stem Cell Transplant.
Ribavirin

B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Clinical Trial using alisertib; romidepsin; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Trial of MLN8237 Plus Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas.
alisertib; romidepsin; laboratory biomarker analysis

Leukemia, or Lymphoma Clinical Trial using Rituximab; Lenalidomide

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Combination of Lenalidomide and Rituximab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL) as Initial Treatment or Subsequent Therapy.
Rituximab; Lenalidomide

Chronic Lymphocytic Leukemia (CLL) Clinical Trial using Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide

Hackensack University Medical Center - Recruiting 18 years or older.
- Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance.
Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide

Acute Myelogenous Leukemia (AML) in 1st or Subsequent Remission, Clinical Trial using POL6326; Leukapheresis; PBSC Transplant

Polyphor Ltd. - Recruiting 18 years to 75 years.
- A Phase I/II Study Evaluating the Safety and Efficacy of Intravenous POL6326 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies.
POL6326; Leukapheresis; PBSC Transplant

Chronic Lymphocytic Leukemia, or Mantle Cell Lymphoma Clinical Trial using Ublituximab; Ibrutinib

TG Therapeutics, Inc. - Recruiting 18 years or older.
- A Multi-center Phase II Study With Safety Run-in Evaluating the Efficacy and Safety of Ublituximab in Combination With Ibrutinib in Patients With Select B-Cell Malignancies.
Ublituximab; Ibrutinib

Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Clinical Trial using Ibrutinib; Bendamustine hydrochloride; Rituximab; Placebo

Janssen Research & Development, LLC - Recruiting 18 years or older.
- Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Ibrutinib; Bendamustine hydrochloride; Rituximab; Placebo

Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocyti Clinical Trial using ibrutinib; rituximab; bendamustine hydrochloride; laboratory biomarker analysis; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting 65 years or older.
- A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (ò 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL).
ibrutinib; rituximab; bendamustine hydrochloride; laboratory biomarker analysis; quality-of-life assessment

Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, or Chronic L Clinical Trial using SAR245409

Sanofi - Recruiting 18 years or older.
- A Phase 1b, Multicenter, Open-Label, Dose Escalation Study of SAR245409 to Evaluate the Safety, Tolerability and Clinical Activity of SAR245409 in Combination With Rituximab or Bendamustine Plus Rituximab in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia.
SAR245409

Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, or Lymp Clinical Trial using BPX-501 and AP1903

Bellicum Pharmaceuticals - Recruiting 18 years to 65 years.
- A Phase 1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells After Partially Mismatched, Related, T Cell-Depleted HSCT (Hematopoietic Stem Cell Transplant).
BPX-501 and AP1903

Acute Myeloid Leukemia Clinical Trial using GRASPA

ERYtech Pharma - Recruiting 65 years to 85 years.
- A Phase IIb Trial Evaluating Efficacy and Tolerability of GRASPA Plus Low-dose Cytarabine vs Low-dose Cytarabine Alone, in Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) Patients, Over 65 Years, Unfit for Intensive Chemotherapy..
GRASPA

Leukemia, Myelodysplastic Syndrome, or Lymphoma Clinical Trial using CliniMACS Fractionation system (Arm A); CliniMACS Fractionation system (Arm B)

Memorial Sloan-Kettering Cancer Center - Recruiting 2 years to 70 years.
- Myeloablative Unrelated Donor Cord Blood Transplantation With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells for Patients With High Risk Hematological Malignancies.
CliniMACS Fractionation system (Arm A); CliniMACS Fractionation system (Arm B)

Acute Myelogenous Leukemia, Diffuse Large B-Cell Leukemia, Chroni Clinical Trial using BMS-936564 (Anti-CXCR4)

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies.
BMS-936564 (Anti-CXCR4)

Leukemia, Multiple Myeloma, Myelodysplastic Syndrome, or Non-Hodg Clinical Trial using Palifermin; Lupron; without the addition of palifermin or Lupron; peripheral blood stem cell transplantation

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years to 60 years.
- An Open Label Randomized Phase II Study of Palifermin With or Without Leuprolide Acetate Versus Control for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation.
Palifermin; Lupron; without the addition of palifermin or Lupron; peripheral blood stem cell transplantation

Pediatric Acute Myeloblastic Leukemia Clinical Trial using Randomisation course 1 mitoxantrone versus DaunoXome; Randomisation course 2 ADxE versus FLADx

Vastra Gotaland Region - Recruiting N/A to 18 years.
- NOPHO-DBH AML 2012 Protocol. Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years.
Randomisation course 1 mitoxantrone versus DaunoXome; Randomisation course 2 ADxE versus FLADx

Chronic Myeloid Leukemia Clinical Trial

Bristol-Myers Squibb - Recruiting 18 years or older.
- Studying Interventions for Managing Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase: The 5-Year Prospective Cohort Study (SIMPLICITY).

Leukemia, Pediatric Clinical Trial using Dasatinib

Bristol-Myers Squibb - Recruiting 1 year to 17 years.
- A Phase 2 Multi-Center, Historically Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia.
Dasatinib

Leukemia Clinical Trial using therapeutic autologous lymphocytes; cyclophosphamide

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase I/IIa Trial For The Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19.
therapeutic autologous lymphocytes; cyclophosphamide

Myelomonocytic Leukemia Clinical Trial using Ruxolitinib

H. Lee Moffitt Cancer Center and Research Institute - Recruiting 18 years or older.
- A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML).
Ruxolitinib

Chronic Phase Chronic Myeloid Leukemia Clinical Trial using Imatinib; Dasatinib

Bristol-Myers Squibb - Recruiting 18 years or older.
- An Open Label, Randomized (2:1) Phase IIb Study of Dasatinib Versus Imatinib in Patients With Chronic Phase Chronic Myeloid Leukemia Who Have Not Achieved an Optimal Response to 3 Months of Therapy With 400 mg Imatinib.
Imatinib; Dasatinib

GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia Clinical Trial using milatuzumab

Immunomedics, Inc. - Recruiting 18 years or older.
- A Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With Hematologic Malignancies.
milatuzumab

Acute Myelogenous Leukemia (AML) Clinical Trial using MK-8242; cytarabine

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase I Study to Evaluate the Safety and Tolerability and Pharmacokinetic/Pharmacodynamics of MK-8242 Administered Alone and in Combination With Chemotherapy in Subjects With Refractory or Recurrent Acute Myelogenous Leukemia (Protocol No. P07649 (005)).
MK-8242; cytarabine

Leukemia Clinical Trial using allogeneic hematopoietic stem cell transplantation; CliniMACS

Memorial Sloan-Kettering Cancer Center - Recruiting N/A to 75 years.
- Randomized Phase II Trial of Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation.
allogeneic hematopoietic stem cell transplantation; CliniMACS

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodyspla Clinical Trial using EPZ-5676

Epizyme, Inc. - Recruiting 18 years or older.
- A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Translocation of the MLL Gene at 11q23 or Advanced Hematologic Malignancies.
EPZ-5676

MDS, CMML, or AML Clinical Trial using SGI-110

Astex Pharmaceuticals - Recruiting 18 years or older.
- A Phase 1-2, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects With Intermediate or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML).
SGI-110

Acute Myeloid Leukemia Clinical Trial using Midostaurin (PKC412); Standard of Care

Novartis - Recruiting 18 years to 60 years.
- A Phase II, Randomized, Comparative Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia.
Midostaurin (PKC412); Standard of Care

Multiple Myeloma, Plasma Cell Leukemia Clinical Trial using ARRY-520, KSP(Eg5) inhibitor; intravenous; Bortezomib, proteasome inhibitor; intravenous or subcutaneous; Dexamethasone, steroid; oral; Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

Array BioPharma - Recruiting 18 years or older.
- .
ARRY-520, KSP(Eg5) inhibitor; intravenous; Bortezomib, proteasome inhibitor; intravenous or subcutaneous; Dexamethasone, steroid; oral; Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

Prostatic Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Mela Clinical Trial using Interactive Voice Response (IVR) Reminders

Michigan State University - Recruiting 21 years or older.
- Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR.
Interactive Voice Response (IVR) Reminders

Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma Clinical Trial using PCI-32765

Pharmacyclics - Recruiting 65 years or older.
- An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil).
PCI-32765

Acute Lymphocytic Leukemia, or Adult Lymphoblastic Lymphoma Clinical Trial using DNR; VCR; PEG-asp; CTX; Prednisone; Liposomal AraC; MTX; LCV; AraC; Etoposide; Dasatinib; Rituximab; Hydrocortisone

University of California, San Diego - Recruiting 18 years to 60 years.
- A Phase II Study of Punctual, Cyclic, and Intensive Chemotherapy With Liposomal Cytarabine (Depocytr) CNS Prophylaxis for Adults With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
DNR; VCR; PEG-asp; CTX; Prednisone; Liposomal AraC; MTX; LCV; AraC; Etoposide; Dasatinib; Rituximab; Hydrocortisone

Acute Promyelocytic Leukemia Clinical Trial using Tretinoin and Arsenic Trioxide

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Phase II Study of Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy.
Tretinoin and Arsenic Trioxide

Lymphocytic Leukemia, Chronic Clinical Trial using rituximab [MabThera]; fludarabine; cyclophosphamide

Hoffmann-La Roche - Recruiting 18 years to 70 years.
- Prospective Study of Efficacy and Safety of RFC (Rituximab, Fludarabine, Cyclophosphamide) Regimen as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Favorable Somatic Status.
rituximab [MabThera]; fludarabine; cyclophosphamide

B-cell Chronic Lymphocytic Leukemia Clinical Trial using B-CLL Vaccine; Lenalidomide

Baylor College of Medicine - Recruiting 18 years to 75 years.
- Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide.
B-CLL Vaccine; Lenalidomide

Acute Lymphoblastic Leukemia Clinical Trial

Amgen - Recruiting 15 years or older.
- A Retrospective Analysis of Hematological Relapse Free Survival and Overall Survival in Adult Patients With Philadelphia-Negative B-Precursor Acute Lymphoblastic Leukemia in Complete Hematological Remission With Minimal Residual Disease.

Chronic Lymphocytic Leukemia Clinical Trial using SyB L-0501

SymBio Pharmaceuticals - Recruiting 20 years to 80 years.
- A Multicenter, Open-label Phase II Study of SyB L-0501 in Patients With Chronic Lymphocytic Lymphoma.
SyB L-0501

Lymphocytic Leukemia, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- An Observational Phase IV Non Interventional Study Evaluating Further the Safety of Rituximab in Combination With Various Chemotherapies for the Treatment of Patients With CD20- Positive B-cell Chronic Lymphocytic Leukaemia in Greece.

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma, o Clinical Trial using auranofin

University of Kansas - Recruiting 18 years or older.
- A Phase I Phase II Two-Step Study of the Oral Gold Compound Auranofin in Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)/ Prolymphocytic Lymphoma (PLL).
auranofin

AML Subjects Who Have Failed Prior Systemic Therapy Clinical Trial using ADI-PEG 20

Polaris Group - Recruiting 18 years or older.
- Phase 2 Study of ADI-PEG 20 in Relapsed/Refractory Acute Myeloid Leukemia.
ADI-PEG 20

Leukemia Clinical Trial using Decitabine

M.D. Anderson Cancer Center - Recruiting 60 years or older.
- A Randomized Phase II Study of Two Schedules of Decitabine for Frontline Therapy of Older or Unfit Patients With Acute Myeloid Leukemia (AML).
Decitabine

Thrombocytopaenia Clinical Trial using eltrombopag; placebo

GlaxoSmithKline - Recruiting 18 years or older.
- A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension).
eltrombopag; placebo

Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplasi Clinical Trial using Chemotherapy and antibodies; Miltenyi Biotec CliniMACS; Allogeneic stem cell transplantation

St. Jude Children's Research Hospital - Recruiting N/A to 24 Months.
- HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies.
Chemotherapy and antibodies; Miltenyi Biotec CliniMACS; Allogeneic stem cell transplantation

Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, or Myelod Clinical Trial using Lupron; 18F FLT; Cyclophosphamide; Methotrexate; Tacrolimus; Total Body Irradiation

National Institutes of Health Clinical Center (CC) - Recruiting 8 years to 60 years.
- Multi-Institutional Prospective Pilot Study of Lupron to Enhance Lymphocyte Immune Reconstitution Following Allogeneic Bone Marrow Transplantation in Post-Pubertal Children and Adults With Molecular Imaging Evaluation.
Lupron; 18F FLT; Cyclophosphamide; Methotrexate; Tacrolimus; Total Body Irradiation

Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Clinical Trial using cytarabine; daunorubicin hydrochloride; etoposide; pomalidomide; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years to 65 years.
- A Phase I Study of Pomalidomide Given at the Time of Lymphocyte Recovery Following Induction Timed Sequential Chemotherapy With Cytarabine, Daunorubicin and Etoposide (AcDVP16) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk MDS.
cytarabine; daunorubicin hydrochloride; etoposide; pomalidomide; laboratory biomarker analysis

Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemi Clinical Trial using daunorubicin hydrochloride; cytarabine; decitabine; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years to 65 years.
- Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML).
daunorubicin hydrochloride; cytarabine; decitabine; laboratory biomarker analysis; pharmacological study

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using romidepsin; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction.
romidepsin; pharmacological study

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myel Clinical Trial using lenalidomide; laboratory biomarker analysis

Albert Einstein College of Medicine of Yeshiva University - Recruiting 60 years to 75 years.
- A Phase I/II Study of Lenalidomide Maintenance After Autologous Stem Cell Transplant for Elderly Patients With Acute Myeloid Leukemia (AML).
lenalidomide; laboratory biomarker analysis

Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymph Clinical Trial using bortezomib; filgrastim; autologous hematopoietic stem cell transplantation

Barbara Ann Karmanos Cancer Institute - Recruiting 18 years to 70 years.
- A Pilot Study of Peripheral Blood Hematopoietic Stem Cell Mobilization With the Combination of Bortezomib and G-CSF in Multiple Myeloma and Non-Hodgkin's Lymphoma Patients.
bortezomib; filgrastim; autologous hematopoietic stem cell transplantation

Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myel Clinical Trial using clofarabine; melphalan; allogeneic hematopoietic stem cell transplantation; laboratory biomarker analysis

City of Hope Medical Center - Recruiting 18 years to 75 years.
- Phase II Study of Clofarabine and High-Dose Melphalan Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Myelodysplasia or Acute Leukemia in Remission.
clofarabine; melphalan; allogeneic hematopoietic stem cell transplantation; laboratory biomarker analysis

Leukemia, Hairy Cell Clinical Trial using moxetumomab pasudotox; IV Bag Protectant for Moxetumomab pasudotox

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/ Refractory Hairy Cell Leukemia.
moxetumomab pasudotox; IV Bag Protectant for Moxetumomab pasudotox

Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leu Clinical Trial using fludarabine phosphate; cyclosporine; sirolimus; mycophenolate mofetil; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; total-body irradiation

Fred Hutchinson Cancer Research Center - Recruiting N/A or older.
- A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-Center Trial.
fludarabine phosphate; cyclosporine; sirolimus; mycophenolate mofetil; allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; total-body irradiation

Leukemia, Leukemia, Lymphocytyc, CLL (Chronic Lymphocytic Leukemi Clinical Trial using PCI 32765

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Study of PCI-32765 for Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Need Therapy and Are Older Than 65 or Have a 17p Deletion.
PCI 32765

Multiple Myeloma, or Leukemia, Plasma Cell Clinical Trial using Carfilzomib; Melphalan; Filgrastim

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 75 years.
- Phase I / II Study Of Carfilzomib (CFZ) Intensification Early After Autologous Transplantation (AHCT) For Plasma Cell Myeloma.
Carfilzomib; Melphalan; Filgrastim

B-Cell Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocyto Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Natural History Study of Monoclonal B Cell Lymphocytosis (MBL) and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Acute L Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Relapsed Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation: Screening, Disease Characterization and Natural History.

MDS (Myelodysplastic Syndrome), Myeloproliferative Disorder, Lymp Clinical Trial using Graft Manipulation (CD34+ Selection)

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 80 years.
- Peripheral Blood Stem Cell Allotransplantation For Hematological Malignancies Using Ex Vivo CD34 Selection - a Platform For Adoptive Cellular Therapies.
Graft Manipulation (CD34+ Selection)

Positive Hairy Cell Leukemia, or CD25-Expressing Hairy Cell Leuke Clinical Trial using LMB-2

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for CD25 Positive Hairy Cell Leukemia.
LMB-2

Leukemia Clinical Trial using Decitabine; Idarubicin; Cytarabine; Clofarabine

M.D. Anderson Cancer Center - Recruiting 18 years to 64 years.
- Phase I/II Study of Decitabine (DAC) Followed by Clofarabine, Idarubicin, and Cytarabine (CIA) in Acute Leukemia.
Decitabine; Idarubicin; Cytarabine; Clofarabine

Lymphoblastic Leukemia, or Lymphoblastic Lymphoma Clinical Trial using Daunorubicin; Vincristine; PEG-asparaginase; Intrathecal Methotrexate; Cyclophosphamide; Cytarabine; Mercaptopurine; Methotrexate; Doxorubicin; Thioguanine

M.D. Anderson Cancer Center - Recruiting 12 years to 40 years.
- Augmented Berlin-Frankfurt-Munster Therapy for Adolescents/Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma.
Daunorubicin; Vincristine; PEG-asparaginase; Intrathecal Methotrexate; Cyclophosphamide; Cytarabine; Mercaptopurine; Methotrexate; Doxorubicin; Thioguanine

Leukemia, Lymphoma, Allogeneic Haematopoietic Stem Cell Transplan Clinical Trial using Busulfan; Clofarabine; Thymoglobulin; Stem Cell Transplant

M.D. Anderson Cancer Center - Recruiting N/A to 65 years.
- Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Acute Lymphoblastic Leukemia or Lymphoma, or Biphenotypic Leukemia.
Busulfan; Clofarabine; Thymoglobulin; Stem Cell Transplant

Acute Lymphobkastic Leukemia Clinical Trial using Vincristine; Daunorubicin; Prednisone; L-asparaginase; Ciclophosphamide; Metotrexate; ARA-C; Hidrocortisone; Mercaptopurine; VP-16; Dexametasone

PETHEMA Foundation - Recruiting 15 years or older.
- Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute.
Vincristine; Daunorubicin; Prednisone; L-asparaginase; Ciclophosphamide; Metotrexate; ARA-C; Hidrocortisone; Mercaptopurine; VP-16; Dexametasone

Chronic Myeloid Leukemia Clinical Trial using Nilotinib, Imatinib

Seoul St. Mary's Hospital - Recruiting 18 years or older.
- A Phase III Multi-center, Open-label, Randomized Study of the Efficacy of Nilotinib Versus Imatinib in Adult Patients With Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib.
Nilotinib, Imatinib

Acute Lymphoblastic Leukemia Clinical Trial using inotuzumab ozogamicin; FLAG (fludarabine, cytarabine and G-CSF); HIDAC (high dose cytarabine); cytarabine and mitoxantrone

Pfizer - Recruiting 18 years or older.
- An Open-Label, Randomized Phase 3 Study Of Inotuzumab Ozogamicin Compared To A Defined Investigator's Choice In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL).
inotuzumab ozogamicin; FLAG (fludarabine, cytarabine and G-CSF); HIDAC (high dose cytarabine); cytarabine and mitoxantrone

Myelodysplastic Syndrome, or Leukemia Clinical Trial using Cord Blood Infusion; Busulfan; Fludarabine; Rituximab; ATG; Cyclophosphamide; Clofarabine; Total Body Irradiation (TBI); Melphalan; Tacrolimus; Mycophenolate Mofetil; G-CSF

M.D. Anderson Cancer Center - Recruiting 1 year to 80 years.
- Cord Blood Expansion on Mesenchymal Stem Cells.
Cord Blood Infusion; Busulfan; Fludarabine; Rituximab; ATG; Cyclophosphamide; Clofarabine; Total Body Irradiation (TBI); Melphalan; Tacrolimus; Mycophenolate Mofetil; G-CSF

Chronic Myeloid Leukemia or Ph Positive ALL Clinical Trial

Seoul St. Mary's Hospital - Recruiting 18 years or older.
- Patterns of ABL Mutation in Asian With Imatinib Resistant Chronic Myeloid Leukemia and Ph Positive Acute Lymphocytc Leuekmia Patients (AMICA): A Retrospective Feasibility Study.

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adul Clinical Trial using DEC-205/NY-ESO-1 fusion protein CDX-1401; poly ICLC; decitabine; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Study of DEC205mAb-NY ESO 1 Fusion Protein (CDX-1401) Given With Adjuvant polyICLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) in Patients With MDS or Low Blast Count AML.
DEC-205/NY-ESO-1 fusion protein CDX-1401; poly ICLC; decitabine; laboratory biomarker analysis

Leukemia, or Lymphoma Clinical Trial using valproic acid; western blotting; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Epigenetic Therapy With Valproic Acid, an HDAC Inhibitor, in Refractory/Relapsed Non-Hodgkin Lymphoma, Hodgkin's Disease and CLL.
valproic acid; western blotting; laboratory biomarker analysis; pharmacological study

Acute Myeloid Leukemia, or Chronic Lymphocytic Leukemia Clinical Trial using SG2000

Spirogen - Recruiting 18 years to 60 years.
- An Open-Label, Phase 1/Phase 2 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of the DNA Minor Groove Binding Agent SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia.
SG2000

Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Clinical Trial using filgrastim; allogeneic bone marrow transplantation; peripheral blood stem cell transplantation

National Cancer Institute (NCI) - Recruiting 16 years to 65 years.
- A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies.
filgrastim; allogeneic bone marrow transplantation; peripheral blood stem cell transplantation

Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Sta Clinical Trial using MOR00208; lenalidomide; Correlative Studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years to 80 years.
- A Phase II Study of MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)Prolymphocytic Leukemia (PLL) or Patients With Untreated CLL/SLL/PLL.
MOR00208; lenalidomide; Correlative Studies

Childhood Langerhans Cell Histiocytosis, Fanconi Anemia, Leukemia Clinical Trial using anti-thymocyte globulin; busulfan; cyclophosphamide; fludarabine phosphate; melphalan; methylprednisolone; radiation therapy

National Cancer Institute (NCI) - Recruiting N/A to 21 years.
- The Use Of Umbilical Cord Blood As A Source Of Hematopoietic Stem Cells.
anti-thymocyte globulin; busulfan; cyclophosphamide; fludarabine phosphate; melphalan; methylprednisolone; radiation therapy

Chronic Lymphocytic Leukemia (CLL), or Small Lymphocytic Lymphoma Clinical Trial using Idelalisib; Rituximab

Gilead Sciences - Recruiting 65 years or older.
- A Phase 2 Single Arm Study to Investigate the Safety and Clinical Activity of Idelalisib Alone and in Combination With Rituximab in Elderly Subjects With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.
Idelalisib; Rituximab

Chronic Lymphocytic Leukemia, 17 p Deletion, or Cancer of the Blo Clinical Trial using ABT-199

AbbVie - Recruiting 18 years or older.
- A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia Harboring the 17p Deletion.
ABT-199

Acute Myeloid Leukemia, Infantile Leukemia (Both AML and ALL), My Clinical Trial using Sorafenib; Cytarabine; Clofarabine

St. Jude Children's Research Hospital - Recruiting N/A to 31 years.
- A Pilot Pharmacokinetic, Pharmacodynamic and Feasibility Study of Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies.
Sorafenib; Cytarabine; Clofarabine

Acute Lymphocytic Leukaemia Clinical Trial using SAR3419

Sanofi - Recruiting 16 years or older.
- Phase II Two Stage Finding Run-in Study of SAR3419, An Anti-CD19 Antibody-Maytansine Conjugate, Administered as a Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia.
SAR3419

Leukemia Clinical Trial using Ruxolitinib; TKI

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Phase I-II Study of Ruxolitinib (INCB18424) for Patients With Chronic Myeloid Leukemia (CML) With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors.
Ruxolitinib; TKI

Leukemia Clinical Trial using ATRA; ATO; GO (Gemtuzumab ozogamicin); Methylprednisolone

M.D. Anderson Cancer Center - Recruiting 10 years or older.
- Phase II Study of Treatment of Acute Promyelocytic Leukemia (APL) With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin (GO).
ATRA; ATO; GO (Gemtuzumab ozogamicin); Methylprednisolone

CD19+ Leukemia Clinical Trial using Patient Derived CD19 specific CAR T cells also expressing an EGFRt

Seattle Children's Hospital - Recruiting 1 year to 26 years.
- Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-02: A Phase 1/2 Feasibility and Safety Study of CD19-CAR T Cell Immunotherapy for CD19+ Leukemia.
Patient Derived CD19 specific CAR T cells also expressing an EGFRt

Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic M Clinical Trial using iTreg

Masonic Cancer Center, University of Minnesota - Recruiting 18 years to 75 years.
- Dose Escalation Study With Extension of Inducible Regulatory T Cells (iTregs) in Adult Patients Undergoing Non-Myeloablative HLA Identical Sibling Donor Peripheral Blood Stem Cell Transplantation.
iTreg

Leukemia Clinical Trial using E7070; Idarubicin; Cytarabine; Dexamethasone

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase 2 Study of E7070, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-risk Myelodysplastic Syndromes.
E7070; Idarubicin; Cytarabine; Dexamethasone

Patients With B Cell ALL, Relapsed or Refractory, With no Availab Clinical Trial using CART-19 cells

Abramson Cancer Center of the University of Pennsylvania - Recruiting 18 years or older.
- PHASE II STUDY OF REDIRECTED AUTOLOGOUS T CELLS ENGINEERED TO CONTAIN ANTI-CD19 ATTACHED TO TCR AND 4-1BB SIGNALING DOMAINS IN PATIENTS WITH CHEMOTHERAPY RESISTANT OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA.
CART-19 cells

Leukemia Clinical Trial using Busulfan; Fludarabine; Alloreactive NK infusion; Interleukin-2; Thymoglobulin; Stem Cell Infusion; G-CSF; Tacrolimus; Methotrexate

M.D. Anderson Cancer Center - Recruiting N/A to 65 years.
- Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies.
Busulfan; Fludarabine; Alloreactive NK infusion; Interleukin-2; Thymoglobulin; Stem Cell Infusion; G-CSF; Tacrolimus; Methotrexate

Acute Myeloid Leukemia, or Myelodysplastic Syndromes Clinical Trial using CD8+ T-cell depleted donor lymphocyte infusion

National University Hospital, Singapore - Recruiting 21 years to 90 years.
- Preemptive CD8+ T-cell Depleted Donor Lymphocyte Infusion (DLI) Following Nonmyeloablative Stem Cell Transplantation (NMT) for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS).
CD8+ T-cell depleted donor lymphocyte infusion

CLL, or Leukemia Clinical Trial using Eltrombopag

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase II Trial of Eltrombopag for Patients With Chronic Lymphocytic Leukemia (CLL) and Thrombocytopenia.
Eltrombopag

B-cell Adult Acute Lymphoblastic Leukemia, Philadelphia Chromosom Clinical Trial using cytarabine; daunorubicin hydrochloride; vincristine sulfate; dexamethasone; methotrexate; pegaspargase; cyclophosphamide; mercaptopurine tablet; blinatumomab; etoposide; prednisone; allogeneic hematopoietic stem cell transplantation; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 35 years to 70 years.
- A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults.
cytarabine; daunorubicin hydrochloride; vincristine sulfate; dexamethasone; methotrexate; pegaspargase; cyclophosphamide; mercaptopurine tablet; blinatumomab; etoposide; prednisone; allogeneic hematopoietic stem cell transplantation; laboratory biomarker analysis

Leukemia Clinical Trial using cyclophosphamide; modified T cells

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase I Trial of Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab.
cyclophosphamide; modified T cells

Stem Cell Transplantation, Leukemia, or Lymphoma Clinical Trial using Thiotepa; Clofarabine; Busulfan; Allogeneic Stem Cell Transplantation; Thymoglobulin (ATG); G-CSF (Filgrastim)

M.D. Anderson Cancer Center - Recruiting N/A to 60 years.
- Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies.
Thiotepa; Clofarabine; Busulfan; Allogeneic Stem Cell Transplantation; Thymoglobulin (ATG); G-CSF (Filgrastim)

Small Lymphocytic Lymphoma, or Chronic Lymphocytic Leukemia Clinical Trial using ABT-199; Rituximab

AbbVie - Recruiting 18 years or older.
- A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.
ABT-199; Rituximab

Chronic Myelogenous Leukemia in Chronic Phase Clinical Trial using nilotinib

Novartis - Recruiting 18 years or older.
- A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP).
nilotinib

Aplastic Anemia, Leukemia, or Myelodysplastic Syndrome Clinical Trial using Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.; CliniMACS device

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- A Multicenter Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine.
Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.; CliniMACS device

Leukemia, or Myelodysplastic Syndrome Clinical Trial using ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- Phase I Trial of Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies.
ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195

Leukemia, Myeloid Clinical Trial using autologous hematopoietic cell transplantation

Asan Medical Center - Recruiting 15 years to 65 years.
- Phase 2 Study of Autologous Hematopoietic Cell Transplantation for Core-binding Factor Positive Acute Myeloid Leukemia in the First Complete Remission.
autologous hematopoietic cell transplantation

Head and Neck Cancers Clinical Trial using Cerenkov emissions from the PET tracer 18F-FDG and the radiotherapeutic 131I

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Non-Invasive Cerenkov Luminescence Imaging of Lymphoma, Leukemia and Metastatic Lymph Nodes.
Cerenkov emissions from the PET tracer 18F-FDG and the radiotherapeutic 131I

Chronic Myeloid Leukemia Clinical Trial using PEG-IFN-a2b

University of Michigan Cancer Center - Recruiting 18 years or older.
- A Combination of Imatinib or Nilotinib Together With Pegylated Interferon-à2b in Chronic-Phase Chronic Myeloid Leukemia: A Phase II Pilot Study Targeting Both the Primitive and Differentiated CML Progenitor Populations.
PEG-IFN-a2b

Leukemia, Acute Lymphoblastic, Precursor B-Cell Lymphoblastic Leu Clinical Trial using Diagnosed as ALL

Asan Medical Center - Recruiting 15 years or older.
- Prospective Observational Cohort Registry for Patients With Acute Lymphoblastic Leukemia at Asan Medical Center.
Diagnosed as ALL

Myelodysplastic Syndrome, or Acute Myeloid Leukemia Clinical Trial using BX2; BX3; BX4

Institut Paoli-Calmettes - Recruiting 18 years to 65 years.
- Prospective and Multicentre Evaluation of 3 Different Doses of IV Busulfan Associated With Fludarabine and Thymoglobuline in the Conditioning of Allogeneic Stem Cell Transplantation (SCT) From a Matched Related or Unrelated Donor in Patients With Poor Prognosis Myeloid Malignancies.
BX2; BX3; BX4

Stem Cell Leukemia of Unclear Lineage, or Graft Versus Host Disea Clinical Trial using extracorporeal photopheresis

University of Kansas - Recruiting 18 years or older.
- A Study of Extracorporeal Photopheresis With UVADEXr in the Setting of a Standard Myeloablative Conditioning Regimen in Related or Unrelated Donor Hematopoietic Stem Cell Transplantation for the Prevention of Graft Versus Host Disease.
extracorporeal photopheresis

Acute Lymphoblastic Leukemia, or Philadelphia Chromosome Clinical Trial using Standard chemotherapy + Imatinib

Rennes University Hospital - Recruiting 1 year to 18 years.
- An Open-label, Phase II Study to Explore the Safety and Efficacy of Imatinib With Chemotherapy in Pediatric Patients With Ph+ / BCR-ABL+ Acute Lymphoblastic Leukemia (Ph+ALL).
Standard chemotherapy + Imatinib

Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Clinical Trial using asparaginase; daunorubicin hydrochloride; mitoxantrone hydrochloride; sorafenib tosylate; cytarabine; etoposide; bortezomib; pharmacological study; laboratory biomarker analysis; questionnaire administration; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting N/A to 29 years.
- A Phase III Randomized Trial for Patients With de Novo AML Using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD.
asparaginase; daunorubicin hydrochloride; mitoxantrone hydrochloride; sorafenib tosylate; cytarabine; etoposide; bortezomib; pharmacological study; laboratory biomarker analysis; questionnaire administration; quality-of-life assessment

Leukemia, Myeloid, Acute, or Myelodysplastic Syndromes Clinical Trial using decitabine

Washington University School of Medicine - Recruiting 18 years or older.
- Genomic Predictors of Decitabine Response in AML/MDS.
decitabine

Acute Myeloid Leukemia Clinical Trial using Liposomal amphotericin B

Bayside Health - Recruiting 18 years to 80 years.
- A Randomised, Stratified, Open Label, Phase II Pilot Study on the Safety of a Daily, Intermittent, or Weekly Administration of 1, 3 or 10mg/kg of AmBisomer in Antifungal Primary Prophylaxis of High-Risk Patients With Acute Myeloid Leukaemia.
Liposomal amphotericin B

Leukemia Clinical Trial using Rituximab; Imatinib; Cyclophosphamide; Doxorubicin; Mesna; VSLI; Solu-Medrol; Methotrexate; Ara-C; G-CSF; Pegfilgrastim; Dexamethasone

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Hyper-CVAD With Liposomal Vincristine (Hyper-CMAD) in Acute Lymphoblastic Leukemia.
Rituximab; Imatinib; Cyclophosphamide; Doxorubicin; Mesna; VSLI; Solu-Medrol; Methotrexate; Ara-C; G-CSF; Pegfilgrastim; Dexamethasone

Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leu Clinical Trial using temozolomide; veliparib; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of the PARP Inhibitor ABT-888 in Combination With Temozolomide in Acute Leukemias.
temozolomide; veliparib; pharmacological study; laboratory biomarker analysis

Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chr Clinical Trial using total-body irradiation; thiotepa; fludarabine phosphate; allogeneic hematopoietic stem cell transplantation; T cell-depleted hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; tacrolimus; methotrexate; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting N/A to 21 years.
- A Phase II Study of Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children.
total-body irradiation; thiotepa; fludarabine phosphate; allogeneic hematopoietic stem cell transplantation; T cell-depleted hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; tacrolimus; methotrexate; laboratory biomarker analysis

For Donors:, Related Donors Donating PBSC to a Family Member, For Clinical Trial using Plerixafor

Center for International Blood and Marrow Transplant Research - Recruiting 18 years to 65 years.
- A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies.
Plerixafor

Acute Lymphoblastic Leukemia, Non Hodgkins Lymphoma, Myelodysplas Clinical Trial using Ara-C; Cyclophosphamide; Campath-1H; Total Body Irradiation; Stem Cell Infusion

Baylor College of Medicine - Recruiting N/A to 55 years.
- CD-34 Selection for Ex-vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts Receiving Intensive Conditioning.
Ara-C; Cyclophosphamide; Campath-1H; Total Body Irradiation; Stem Cell Infusion

Acute Lymphoblastic Leukemia Clinical Trial using Metformin; Vincristine; Dexamethasone; PEG-asparaginase; Doxorubicin; Intrathecal chemotherapy

H. Lee Moffitt Cancer Center and Research Institute - Recruiting 1 year to 30 years.
- A Phase I Window, Dose Escalating and Safety Trial of Metformin in Combination With Induction Chemotherapy in Relapsed Refractory Acute Lymphoblastic Leukemia: Metformin With Induction Chemotherapy of Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD).
Metformin; Vincristine; Dexamethasone; PEG-asparaginase; Doxorubicin; Intrathecal chemotherapy

Leukemia Clinical Trial using Nelarabine

M.D. Anderson Cancer Center - Recruiting N/A or older.
- A Pharmacokinetic and Pharmacodynamic Study to Evaluate the Safety and Feasibility of Continuous Infusion Nelarabine in Patients With Relapsed / Refractory Lymphoid Malignancies.
Nelarabine

Primary Myelofibrosis, Post-Polycythemic Vera Myelofibrosis, or P Clinical Trial using NS-018

NS Pharma, Inc. - Recruiting 18 years or older.
- A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF.
NS-018

Chronic Lymphocytic Leukemia (CLL) Clinical Trial using Autologous tumor cell extract vaccine

Xeme Biopharma Inc. - Recruiting 18 years or older.
- A Phase Ib Trial of Oncoquest-CLL Vaccine for Treatment-Naive Patients With Chronic Lymphocytic Leukemia.
Autologous tumor cell extract vaccine